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Abstract
This Global Studies honors thesis addresses how managers and leaders of global firms
manage innovation across multiple markets. Current research on multinational
corporations provides an understanding of different kinds of innovation and the ways to
attend to multiple markets. However, there is less documentation of how these innovation
strategies are actually implemented on the ground and the tensions that these efforts
might produce. Therefore, my research focuses in particular on the challenges and
tensions faced by leaders of global firms as they implement transnational innovation
strategies. This study is based upon in-depth interviews with 20 participants who held
positions in global companies in the pharmaceutical and technology industries	
  as	
  well	
  as	
  
academics	
  whose	
  work	
  addresses	
  organizational	
  management	
  and	
  innovation.
Results from an analysis of these interviews across and within these two industries
provide insights into the literature on multinational	
  corporation	
  global	
  innovation	
  and
leadership across international borders.
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Chapter 1: Introduction
In an increasingly globalized and interconnected world, new forms of innovation
and strategy within multinational firms have evolved to address the needs of consumers
worldwide. Various theories of innovation seek to address how global companies can
capture the value of growth and opportunity in new markets while also providing for the
needs of core consumers in their home country’s markets. Every market has distinct and
varying needs and wants, and firms must innovate and customize for local consumers if
they hope to remain competitive in the coming decades. For example, these days, rather
than innovating in developed countries such as the United States and then selling these
innovations to developing countries, the reverse approach is also important
(Govindarajan and Trimble, 2012). That is, multinational organizations can gain a
competitive advantage from developing strategic innovations that target developing
countries; they can then use those insights and innovations to be even more competitive
around the globe. Although there have been significant advances in innovation and
management theory, my research focuses specifically on the organizational systems,
structures, and leadership strategies that enable multinational firms to implement
successful global innovation strategies to provide for the needs of multiple markets
around the world.

Research Question
My research question addresses how multinational companies employ
organizational structures and systems in multiple country contexts for successful
implementation of global innovation strategies. I look specifically at leadership,
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operations, and innovation in the technology and pharmaceutical industries. My research
examines how multinationals in these industries explore multiple markets, how they
create information flows between local partners and global firms, how senior managers
lead transnational innovation initiatives, and how they maintain global brand while also
providing for consumers in new geographic markets.

Significance of the Research Question
Through my investigation of this research question, I hope to improve our
understanding of how to address the needs of multiple consumers across international
borders. Further, I aim to contribute to the literature on the management of innovation on
a global scale. Although prior research has examined different kinds of innovation
strategies and cross-cultural tensions associated with leading across borders, there is little
research on the implementation strategies that leaders can employ to address those
challenges. I look more closely at the implementation of global innovation strategies and
how multinational companies employ organizational structures and systems in multiple
country contexts to successfully implement these strategies. Specifically, I examine how
these innovation strategies are managed on the ground through the use of formal
structures, such as local teams, as well as systems, such as specific methods of
communication and information transfer. I look specifically at two industries –
technology and pharmaceuticals – to expand upon current research as to how managers
explore new global markets, create information flows between local partners and global
firms, lead transnational innovation initiatives, and maintain global brands while also
providing for new consumers.
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In their book, Reverse Innovation, Govindarajan and Trimble (2012) suggest that
additional research is needed to understand the implementation of innovation across
developed and developing countries. Their work provides insights into the steps that
multinationals can take to shift a portion of the company’s focus and attention to local
market customization. For example, they suggest relocating some executives to
developing countries and assigning them to oversee these markets in the Global South.
Firms may also increase their spending in emerging markets to focus on innovation for
local needs. Specifically, multinationals may need to undertake field experiments to try
out their ideas and to better understand local knowledge and needs. Further, it is
important that multinationals increase their knowledge of emerging markets within the
firm itself, this could entail hiring leaders with experience and expertise in these specific
markets. In addition, employees of global companies could be assigned specifically to the
investigation of the other countries to fully immerse themselves in these cultures to best
understand them (Govindarajan and Trimble, 2012).
One strategy for implementing locally customized innovations that seems to be
employed in many instances is the use of local growth teams (LGTs) located in particular
markets whose role would be to analyze and understand the needs of these consumers and
then create new innovative products for this specific market (Govindarajan and Trimble,
2012). LGTs would not be in lieu of current organizational strategies but rather would
supplement them. Govindarajan and Trimble suggest hiring outside the organization to
better undertake idea generation and truly apply a “clean-slate” approach to consider
local market needs.
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Through my interviews with senior management as well as through academic
research, I explore some of these implementation strategies that leaders of global
organizations employ and the tensions and challenges they face in managing across
cultural borders. In this way, my research contributes to our understanding of global
innovation strategies to better address the needs of multiple global consumers. I also
provide insight into how multinational corporations from the technology and
pharmaceutical sectors manage local and global relationships to provide consumers from
different markets with products for their particular needs. Additionally, by interviewing
senior leaders of global firms, I improve our understanding of how leaders of
multinational corporations manage cross-cultural boundaries, including the kinds of ways
that they learn to adapt their styles and strategies to manage different constituencies.

Personal Motivation for the Research
My interests in cross-cultural innovation management stem from my work both at
Colby and abroad and from time spent in work settings as well. As a Colby Freshman, in
Dijon France, I was fortunate to learn a great deal about French culture and how to
navigate across borders. I lived with a host family and felt entirely immersed in this new
culture and environment. This was where I truly developed an appreciation for the
importance of understanding various cultural contexts.
Additionally, during my semester abroad in Geneva, Switzerland, I interned for a
global strategy consulting firm where most of my work involved attending sessions at the
United Nations (UN) and summarizing my findings from these meetings for my boss and
her clients. During my work with this firm and at the UN, I undertook an independent
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research project, which examined the impact of foreign direct investment on developing
countries. My work at the UN as well as my research project abroad as a Colby Junior
truly sparked my interest in the relationship between developed countries, such as the
U.S., and developing countries, such as those in Africa that I studied for this research
project. I was particularly drawn toward understanding how multinational organizations
can serve needs in various different parts of the world simultaneously and how it is
possible to see and manage these diverse opportunities in a way that improves the
company’s effectiveness overall – how serving multiple markets can be helpful for
customers and can improve the performance of the firm overall. When originally thinking
about global innovation I was especially intrigued by the notion of serving the
underserved – that is, serving consumers in developing country markets or small market
spaces not previously served by large companies. Global innovation strategies that focus
specifically on meeting consumer needs in various communities across the globe address
this relationship between developed and developing countries. Overtime, my
investigation into global innovation broadened to also consider how organizations with
global reach strive to adapt to local needs, and in this way serve multiple consumers,
whether or not they were previously underserved.
My interest in business management and strategic analyses of firms’ internal
operations stems from an integration of my global studies and economics courses. In
particular, my economics of globalization coursework has helped me to better understand
the factors that affect multinational corporations today – such as the global value chain
and intellectual property rights. Further, coursework for my managerial economics minor
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has complemented my work in Global Studies and has helped me to better comprehend
the management of global firms.
I became particularly drawn to the topic of global innovation strategy during my
studies at the Tuck Business School where I participated in a rigorous summer business
management program the summer prior to my junior year. One of the classes that I took
while at Tuck was taught by Vijay Govindarajan, one of the scholars who developed the
theory of reverse innovation that has launched my investigation into the management of
global innovation for my thesis. I began to read his book immediately after the course
was over, was interested in the ideas, and wanted to learn much more.
For these reasons, I have been intrigued by global innovation strategy and have
become more and more convinced that understanding how to implement strategies for
country cultures that are not our own - are not based solely upon American customer
needs -- will be beneficial for those in different countries. Through this work, I improve
our understanding of how to create effective organizational systems and structures to
effectively innovate and provide products for consumers in various global markets. I also
shed light on the tensions these organizations face as they strive to serve multiple markets
and the ways in which organizations in different sectors, such as technology and
pharmaceuticals, might employ different strategies to manage these tensions. Ultimately,
with my research, I contribute to efforts that help guide multinational corporations toward
a set of best practices when implementing a global innovation strategy - showing how to
best provide for multiple communities across the globe while maintaining global brand
and reputation. 	
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Chapter 2: Literature Review
To ground my research on the implementation of cross-cultural innovation
strategies in global companies, I draw upon three relevant streams of research. First, there
is the research directly on the topic of innovation strategies. This is important literature to
understand for the purposes of juxtaposing newer approaches to innovation with more
established theories of innovation in the field. Second, there is research on multinational
firms and specifically on the management of global-local tensions. Third, there is
research on the importance of local customization to address the specific needs of
different consumers in various market spaces. Together, these three streams of research
will inform my work on the use of organizational structures and systems in multiple
country contexts to implement global innovation strategies. I provide an overview of each
research stream in turn.

Innovation Strategies
Understanding different innovation strategies in large corporate settings is key to
understanding how multinational companies might choose to organize systems differently
to manage innovation across borders. Large companies are often considered entrenched
and unlikely to change (Tushman and O’Reilly, 2002); innovation, in general, is a
difficult concept to effectively manage. Numerous scholars have tackled the subject of
innovation and have explored different approaches to innovation in large firms and in
firms that cross international borders, lending insight into the kinds of strategies
multinational organizations may choose to employ.
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Reverse Innovation. Govindarajan and Trimble introduced the term “reverse
innovation” (2012) to refer to the process by which innovation originates in emerging
markets, rather than in markets that are more established. Reverse innovation thus goes
against the typical understanding of how the world does and should innovate as promoted
by other scholars such as Tushman and O’Reilly (2002). Instead of innovating in wealthy
countries and then transferring this technology to the developing world, reverse
innovations are developed first in the developing world and then generally spread to
developed countries.
The theory of reverse innovation was first developed based on the understanding
of a need for consumer customization, particularly in emerging markets. Developing
world needs are not equivalent to the needs of consumers in emerging markets; one must
take into account differing conditions that create demand for different types of products
(Govindarajan and Trimble, 2012). It is no longer sufficient to create lower-end models
of rich-country products and market these models in the developing world. It is necessary
instead to address differences in geography, culture, language, government, and
infrastructure (Govindarajan and Trimble, 2012). Further, by examining and targeting
different developing country needs, multinationals have the opportunity to reconsider
their own biases and assumptions and thus, to innovate more effectively using these
insights from their work in developing countries to be more competitive in their home
marketplace.
The most prominent authors within the field of reverse innovation are the two
academic scholars who developed this theory themselves, Vijay Govindarajan and Chris
Trimble. Their Reverse Innovation (2012) gives an overview of the theory itself and the
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means by which a company could go about implementing it. Govindarajan and Trimble
then move into a series of case studies to show how senior management in numerous
multinationals have been able to tap into emerging markets successfully using their
theory.
There are many examples of reverse innovation that have effectively scaled from
emerging markets to the developed world. For example, Kiva is a microfinance enterprise
that makes it easy for entrepreneurs in developing countries to acquire loans to help lift
themselves out of poverty. This program has expanded its reach to U.S. citizens in need
of microfinance loans as well (Carus, 2012). Similarly, the product Gatorade was
originally developed in South Asia to aid cholera patients with hydration. It then spread
to the U.S. and around the world as a hydrating sports drink. Another innovation we can
point to as an example of reverse innovation is the Tata Nano, an electric car originally
created for price conscious consumers in India that has now spread to markets in the U.S.
and Europe (Govindarajan and Trimble, 2012).
While there are few direct critics of the strategy of reverse innovation, there are
some who have argued that the concept is not entirely new and further, that it is not
applicable to organizations that are not multinational in scope. For example, Phillips
argues that reverse innovation is a strategy that only addresses the needs and expansion of
multinational organizations and does not offer solutions for smaller companies looking to
break into the emerging market space (Phillips, 2013). The above examples of reverse
innovation provide some evidence that one key management structure for implementing
global innovation strategies are local teams. Further, these examples suggest that the
communication between corporate headquarters and these teams is critical to the
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implementation of this global strategy. However, further research and fieldwork could
contribute to a better understanding of the mechanisms that may need to be in place in
order to better implement global innovation strategies.
Frugal Innovation. “Frugal engineering,” a term coined by Carlos Ghosn, CEO
of the Renault-Nissan Alliance, refers to innovating cheaply in resource-constrained
environments (Radjou & Prabhu, 2013). Similar to the theory of reverse innovation,
frugal innovation supports the idea of “doing better with less” (Radjou & Prabhu, 2014).
Frugal innovation is a disruptive growth strategy that looks to create value for consumers
and businesses by reducing the use of scarce resource while still addressing the qualities
most valued by Western consumers: quality, sustainability, and affordability.
Frugal innovations break free from traditional ideas behind innovation in Western
companies. Typically, innovation in Western companies requires a high consumption of
natural resources to create expensive premium product offerings. As researchers have
recently argued, these types of solutions no longer cater to the realities of American and
European markets; consumers are constrained by their budgets and are looking for
products that are not harmful to the environment. Frugal innovations are often inspired by
offerings in emerging markets, where multinationals have long had to provide for lowincome consumers in resource-constrained environments (Radjou & Prabhu, 2013).
Similar to Govindarajan and Trimble, Radjou and Prabhu call for structural and
cultural changes within multinational organizations to undertake this type of innovation
(2014). Unilever is one example of a frugal organization; led by CEO Paul Polman,
Unilever’s strategic orientation has been altered to reduce environmental impact and
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resource usage while providing more affordable, high-quality products to consumers
worldwide (Radjou & Prabhu, 2014).
Disruptive Innovation. More generally and not necessarily in the context of
global research, scholars have focused on the idea of “disruption” as a source of
innovation – how firms can engage in “disrupting” dominant pathways to provide an
alternative to customers that meets an unrecognized need at minimal cost to the customer.
This concept of “disruptive innovation” is attributed to general management scholar
Clayton Christensen, who originally wrote the Innovators Dilemma (1997); his book
discusses the need for adoption of new technology and business models to meet future
needs of consumers or the need for “disruptive innovations.”
The theory of disruptive innovation has since been applied to other market sectors
including but not limited to the original semi-conductor industry (Christensen, 2010).
From this view, the idea is to engage in disrupting dominant markets with new products
and services that can then spread to serve the more traditional buyer. Although some of
Christensen’s theory may overlap with that of Govindarajan and Trimble in that they both
are concerned with disrupting dominant markets, the orientation is different. Where
Govindarajan and Trimble focus on disruption abroad through innovation in emerging
markets, Christensen’s theory focuses on disruption in dominant markets and is not
specifically tied to the needs of emerging or developing country markets.
Christensen’s theory of disruptive innovation can be complemented by the
arguments of Schmidt and Druehl (2008). Schmidt and Druehl purport that disruptive
innovations may not be immediately disruptive, as Christensen’s works propose. Rather,
innovations diffuse in varying ways through a market; they can encroach on the high end
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of an existing market, on the low end, create a fringe market, or create a detached market.
In this way, disruptive innovations may not immediately disrupt a current market, rather,
their impact may vary.
Glocalization. Another approach to innovation and one that is oftentimes
considered in a global context is what may be referred to as “glocalization,” a term
popularized by sociologist Roland Robertson (1995), in which firms gain access to
emerging markets by modifying or altering their current technologies (developed for
wealthy countries) and then marketing these technologies in emerging markets. By
adopting glocalization, Ghemawat’s (2007) aggregation theory purports that similarities
across geographical regions can be exploited to create economies of scale. These
economies of scale can effectively address differences amongst different geographical
regions, without innovating specifically and only for focal markets (Ghemawat, 2007).
Although not effective in all situations, glocalization can help to address the needs in
various rich countries. Further, some developing countries that have similar needs to their
wealthy counterparts may be able to use rich world innovations effectively. As an
example of glocalization, we can consider the brand of Colgate, which is widely
applicable to markets around the world who connect with the brand’s value of physical
beauty (Govindarajan and Trimble, 2012).
Glocalization might be considered a complementary approach to reverse
innovation because it suggests that some innovations that originated in developed
countries may transfer effectively to the developing world. As Govindarajan and Trimble
(2012) suggest, multinational giants that understand when to use which kind of strategy
will be particularly effective in a global marketplace. Critics of this two-sided approach
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could argue that this is an extremely difficult dichotomy to manage across borders and to
understand which strategic approach to use when. Most markets are dynamic and in some
cases, such as new technologies and the life sciences, highly uncertain making it difficult
to know from which direction the innovation might originate.
Using this dual strategy approach, however, involving both reverse innovation
and glocalization, companies might be able to work to understand and address the needs
of customers in the developing world first, and then create a solution more generally
(Govindarajan and Trimble, 2012). That is, it is important not to assume that innovations
from the developed country will necessarily apply to developing country needs. For
example, the high-end product of electrocardiograms, which are widely used in the
developed world, are not an effective product for some developing markets such as India
because they are heavy, expensive, and have extensive power requirements. It is not
necessarily effective to alter existing products from the developed world to be used in the
developing world. Rather, firms should look closely at the needs of the people in a
particular market and come up with new technologies specifically tailored to meet these
needs (Govindarajan and Trimble, 2012).
Acceleration. John Kotter, a famous management scholar, has recently written
the book Accelerate (2014), which focuses on how to build and execute innovative ideas
in large corporations through creative management structures and systems that enable the
ideas of those closest to the work to gain exposure and visibility to senior management.
As Kotter’s (2014) work shows, it is critical to be intentional about the management
structures in place to enable senior leaders to seriously consider innovations as part of
their larger strategy. As Kotter (2014) explains, large corporations are often resistant to
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innovation and also do not have the management structures in place to enable good ideas
from those closest to the customer to be heard by senior leaders.
To address the constraints in technology transfer, Kotter and colleagues
recommend a management process in which an established company explores new areas
of business while continuing to utilize existing business capabilities. A multinational
organization can create an organizational structure that has separate units, such as the
local growth teams that are engaged in exploratory business, while others are tasked with
continuing to exploit current capabilities within the firm. These various units must be
unified with an executive team that is integrated across these units. Businesses that are
able to manage this simultaneous organizational separation and integration are known as
“ambidextrous organizations” (O’Reilly & Tushman, 2004).
Of course, there are many potential fears and issues that come along with any
kind of innovation, particularly if the firm has been successful in the past (Tushman and
O’Reilly, 2002). Many firms fear losing money in the creation of a new type of
technology. However, if they can design and produce products based on lower fixed costs
and with potentially higher volume in poor countries, these low cost products can often
earn the same or even better margins than their higher cost counterparts (Navarro, 2006).
Further, firms may be concerned about cannibalization of premium offerings with new
reverse innovation offerings. However, competing at multiple price points can help a firm
to become more competitive across the world and compete in a larger array of market
spaces. In order to overcome these fears, the firm must consider the high costs to
inaction. By ignoring potential opportunities for innovation entirely, incumbent
multinational giants empower the growth of emerging market companies. These local
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companies can capture emerging markets before their multinational counterparts do, and
multinationals will struggle to catch up and gain a portion of the global market share
(Govindarajan and Trimble, 2012).
In sum, many different theories of innovation have been proposed by management
and organizational scholars, some of which have addressed the specific issue of global
innovation, whereas others have not. As I am interested in global innovation but am open
to considering theories that emerge from other literature that more generally addresses the
tensions inherent in managing across multiple consumer contexts, whether global or
otherwise, I provide this backdrop as a primer to my research and as a reference to refer
back to when interviewing senior managers about global innovation. No one particular
theory fits all interviewees’ experiences nor those of a firm but rather, these theories
provide useful frames of reference for the ideas that the interviewees share.

Managing Multinational Corporations
This discussion of innovation strategies requires a complementary literature on
multinational corporations. Given that my research will be investigating innovation in
the context of multinational organizations, it is important to not only consider the
literature on different innovation strategies but also the literature that specifically focuses
on the challenges faced by multinational corporations. Research suggests that
multinational corporations or MNCs face many challenges associated with executing
their strategies on a global scale.
One major challenge that MNCs face is simply the fact that people are working
across time zones, geographies, and cultures. For example, it may be difficult for those
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closest to the customer to be heard by senior leaders due to the fact that people are
working far apart from one another, making coordination difficult. There is often a
tension that exists between global and local market concerns; according to a number of
scholars studying multinational organizations, global and local activities must be well
coordinated, In particular, the coordination across borders of knowledge, ideas, and
information is a topic of interest that has intrigued scholars who study multinational
teams and knowledge management in complex uncertain environments and is relevant to
my research.
Bartlett and Ghoshall (1998) examines how, in an ever-globalizing world, firms
must employ a global strategy to manage and organize themselves across borders in order
to remain competitive. These scholars illustrate the importance of a transnational strategy
where the competitiveness of a firm is reliant on its ability to employ a carefully planned
global strategy. In related work, according to Garvin and Levesque (2008), multi-unit
enterprises face four main issues associated with operational coordination: consistency,
customization, division of responsibilities, and definition of field manager
responsibilities. They argue that to maintain a firm wide brand, managers must constantly
focus on aligning their decisions with those of the larger corporation. In addition, they
argue that management practices must be customized based on geographies; varying
demographics, skill sets, and wages, amongst other factors, require leaders to adapt their
management styles to manage workers in different locations.
Garvin and Levesque (2008) also address the tensions that exist when dividing
responsibilities amongst firm managers; in particular, this issue tends to create conflicts
between global corporate headquarters and local business units. The solution to these
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problems, according to Garvin and Levesque, is a clear definition of roles within the
multi-unit business as well as the use of managers as “information funnels” to create
manageable data flows and interconnectedness between business units and corporate
headquarters.
Although much research has focused on multinational organizations and their
operations from a central home-country perspective, little has addressed how innovations
actually transfer from one country to another and the use of information flows across
teams. Research by Haas and Cummings (2015) can lend insight here as their work
examines resources such as time and attention and how multinational teams must be
thoughtful when executing their work across both geographic and time boundaries to
utilize these invaluable resources efficiently and effectively. Their conclusions are
helpful in considering how management will form synergistic relationships between its
local teams and the larger multinational organization to create a mutually beneficial
relationship that adds value to the firm rather than creating tension.
Additionally, research by Grossman and Rangan (2001) shows that centralized
organizational units need to maintain consistency and standards within a firm while also
customizing for local needs. Their research looks specifically at non-profit organizations
and their operations; however, similar tensions and ideas apply whether one is examining
the management of nonprofits or multinational corporations. They discuss the tensions
that exist due to business unit’s desire for autonomy in tangent with its need for
affiliation with the global corporation as a whole in order to gain access to firmwide
resources. Strong business units require strong leaders which often lead units to become
increasingly autonomous, disrupting the cohesiveness of the larger corporation.
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Grossman and Rangan argue that to create a sense of unity and integration, managers
should share information and best practices across business units, ultimately
strengthening the larger entity as a whole. The ability of multi-site organizations to
accommodate for business unit autonomy while also creating a sense of integration and
unity can determine the overall success of a firm; as Grossman and Rangan caution,
“sustainable balancing of [autonomy and affiliation] can only be achieved by constant
and diligent management” (336).
Finally, Kanter’s research (2010) gives readers a better understanding of the
leadership challenges faced by the individuals who must actually manage these tensions
across cultural boundaries. Identifying key factors such as uncertainty, complexity, and
diversity, Kanter addresses specific aspects of globalization that alter the ways leaders
must operate in a world that is becoming ever more interconnected. Her work suggests
that it is critical for leaders to understand how to adapt or alter their leadership approach
when working across cultures.

Local Customization in Global Firms
In addition to the literature on innovation and on multinational firms, research on
why firms should customize their products for local needs is also relevant to consider
here. Global organizations must address the distinct needs of local and regional markets
to create the best products for consumers. In addition, marketing and merchandising must
be based on the demographic of the specific consumer base, varying by geography
(Garvin and Levesque, 2008). The need for local customization, particularly in
developing countries, within global innovation strategies stems from five needs gaps that
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exist today in the developing world that create opportunities for clean slate innovations to
be successful. Govindarajan and Trimble (2012) describe these specific gaps in their
book and argue that these gaps between developing and developed countries open up
opportunities for customized innovation to take place.
First, markets require the fulfillment of the performance gap, where products must
meet real needs for consumers in these countries, but at a price that is reasonable for them
to afford. An infrastructure gap also exists, where a lack of reliable infrastructure in
developing countries creates opportunity and an environment for breakthrough
technologies to be implemented immediately, without being burdened by existing models
and infrastructure. There is also a sustainability gap in developing countries, similar to
the infrastructure gap, since, without previous infrastructure in place, emerging markets
are an excellent place for developing countries to immediately implement
environmentally sound technologies. Further, developing countries face a
disproportionate number of environmental challenges in comparison to their developed
counterparts; they therefore depend on environmentally sound technologies to sustain
their economic growth. A regulatory gap can also be filled with reverse innovations in
emerging markets. Developing countries do not have the same highly regulated systems
in place, which can hinder the ability of firms to innovate; thus, developing countries can
actually offer a more hospitable environment for trying out new products or services
because they face fewer regulations than firms operating solely in developed countries.
Finally, a preferences gap between developed and developing countries can create a need
as well; differences in tastes and needs around the world often require “clean-slate”
innovation or products developed specifically for the needs of those in poverty that offer
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multinational companies opportunities in emerging markets as well (Govindarajan and
Trimble, 2012). In sum, great opportunity exists for firms who choose to innovate and
create technologies to address specific global market needs.
There are a number of reasons why firms might undertake an innovation strategy
that requires local customization and partnerships, but oftentimes refrain from doing so.
Typically, marginalized markets are often ignored because their size appears too small to
justify the costs of research and development to create products for them. However,
creating innovations for the developing world can close the needs gaps previously
identified, serve needs that are greater than they first appear, and can offer insights that
can help a global company’s business overall. Further, the cost to multinational giants of
ignoring industry shifts and the needs of the developing world are incredibly high as
these needs often represent areas of market growth and potential. In addition, rich world
infrastructure will eventually age and even the developed world will adopt these sorts of
innovations when existing assets require replacement (Govindarajan and Trimble, 2012).
By drawing upon these streams of research and my own study, I contribute to the
field of innovation in multinational organizations by improving our understanding of how
organizational structures and systems are managed in multiple country contexts to
successfully provide for multiple consumers across different geographic and cultural
contexts. My focus is specifically on the question of how to manage innovation across
international borders and to study the systems and structures used to manage innovation
in the field. This research explores how MNCs explore new geographic markets, create
information flows between local partners and global firms, how senior management leads
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transnational innovation strategies, and how MNCs maintain global brand while
providing for the underserved.
In order to build on the prior research on different innovation strategies,
management of multinational firms, and local customization, I offer several predictions
that stem from the previously mentioned research streams. I note that whereas the first
two hypotheses are expectations about what may be commonly seen across the two
contexts I study – the technology and pharmaceutical industries – the last predication
does make a distinction between the two. There, considering the role of the political and
regulatory environment which I expect is generally more stringent in the pharmaceutical
industry than in the technology industry, I expect to find more restraint with respect to the
use of partnerships as a means of local customization in global innovation strategies for
pharmaceutical companies as opposed to technology companies. My hypotheses follow:

Hypotheses:
1. Leaders of global innovation strategies must manage tensions between addressing
the needs of consumers in emerging markets while also maintaining firm-wide
standards, brand, and reputation and often do so through the use of local
partnerships.
2. Global leaders in multinational corporations must adapt or change their leadership
styles in order to lead innovation initiatives across cultural contexts.
3. Technology firms are more likely to be open to engaging with local partners than
their pharmaceutical counterparts due to the risks that they may endure
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Table 1:
Summary of Innovation Strategies Presented in Literature Review
Innovation Strategy

	
  

Author

Definition

Reverse Innovation

Vijay Govindarajan and
Chris Trimble (2012)

Global companies innovate
for the distinct needs of
emerging market consumers

Frugal Innovation

Carlos Ghosn (2006)

Global companies create
innovations and reduce their
use of scarce resources
while still addressing the
qualities most valued by
consumers

Disruptive Innovation

Clayton Christensen (1997)

“Disrupting” dominant
pathways to provide an
alternative to customers that
meets needs at minimal cost
to the consumer

Glocalization

Roland Robertson (1995)

Global companies create
groundbreaking innovations
for developed market
consumers, then sell in
emerging markets at
reduced price points

Acceleration and
Ambidextrous
Organizations

John Kotter (2014), Charles
O’Reilly and Michael
Tushman (2004)

Intentionally creating
management structures to
enable senior leaders to
consider innovations as part
of larger organizational
strategy
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Chapter 3: Methods
This research is based on data collected between the months of January and
March of 2016. My target population for the interviews was leaders within global
organizations who have been involved in managing innovation strategies across multiple
country markets for their firms. Research included interviews with senior managers of
multinational firms within the technology and pharmaceutical industries. Interviewees in
the technology space came from organizations ranging from finance technologies and
medical technologies to computer, sound, and imaging solutions. Pharmaceutical
interviewees included individuals who held senior-level roles in their organizations such
as Chief Executive Officer, Chief Financial Officer, and Senior Vice President of
Research and Development. Interviewees drew from a variety of experiences including
those in large, and successful organizations, medium-sized organizations, as well as more
entrepreneurial or start-up type organizations.

Data
The data for this research is based upon interviews with top-level global
executives in technology and pharmaceutical companies; all of the interviewees held
positions that were at the C-level (corporate level), such as Chief Executive Officer,
Chief Technology Officer, Chief Commercial Officer, Chief Financial Officer or were
senior-level executives, holding other positions (e.g., Executive Chairman, Senior Vice
President).
My sources for these interviews came from names that were suggested to me
through my faculty advisors at Colby, through professors whose courses I took at Tuck
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Business School, through executives I met after attending an executive program at
Harvard Business School on innovation, and through prior work and/or family contacts. I
employed a snowball sampling technique, in which, following an interview, I asked for
additional possible names. To track interviewee possibilities, I created a spreadsheet of
possible subjects and their contacts and then followed up oftentimes with these senior
leaders’ assistants in order to schedule interviews. In doing so, I created a short overview
of my work, which I include in Appendix A, to give some information about the focus of
my research but not so much as to influence interviewees in any particular way.
In total, I created a possible list of about 35 interviewees and ultimately, was able
to interview twenty of them. Interviews lasted on average approximately 45 minutes in
length. All of these interviews were done remotely, with managers who operated in
various locations across the globe ranging from the United States to Greece to South
Africa.
Through my interviews with senior management as well as through academic
research, my research and interviews were designed to further an understanding of global
innovation strategies that are employed to meet the needs of consumers in multiple
market contexts. In particular, I focused my interviews on exploring the kinds of tensions
and challenges global leaders face in managing across cultural borders. By employing a
comparative perspective, my interviews also aimed to investigate the kinds of
organizational strategies that may be generalized and those that may not, as leaders
pursue innovation strategies across the globe. Finally, through my interviews with senior
leaders of global firms, I sought to ask questions that contribute to our understanding of
how leaders of multinational corporations manage cross-cultural boundaries, including
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the kinds of ways that they learn to adapt their styles and strategies to manage different
constituencies.
Thus, in line with the hypotheses previously outlined, my interview protocol was
organized around the following three questions:
1. Is there tension between innovating to meet the needs of multiple consumers
across geographic borders versus maintaining brand reputation worldwide; if so,
how would these be described?
2. What kinds of tensions do managers involved in global innovation strategies face
in terms of adapting their own personal leadership style as they cross market
cultures?
3. To what extent do managers use local partners to implement their global
innovation strategies? Are there tensions associated with doing so? In particular,
how does the firm protect intellectual property when engaging with local
partners?
More specifically, my interviews were organized around the protocol and sample
questions that can be found in Appendix B.

Analytical Strategy
Throughout my interviews, I sought to stay grounded in my work by asking my
interviewees for examples of what they were describing. This way, I could try to
understand more fully their own perspectives on how they put in place structures to
manage across borders or what kinds of experiences they had encountered when adjusting
their own leadership styles across international borders. After each interview, I wrote up
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detailed notes, trying to capture as much detail as possible from the conversations. This
resulted in approximately 35 pages of notes.
In order to analyze my notes, I worked inductively with the data, looking for
patterns in the kinds of comments that were made separately in each sector. I then
recorded these as “themes” under each research question and created an outline that had
themes and beneath each, specific details from the participant conversations. Following, I
looked across my interviews from both sectors to look for themes that were similar.
Using this process of comparing within and across the detailed notes and the subsequent
outline, I was able to discern what was and was not generalizable from my sample
interviewees. My results were then organized by interview question and by theme, as
written in the chapters that follow.
In addition, I tried to remain open to unexpected ideas, not only in the themes that
emerged but in the topics that my interviewees wanted to discuss. For example, whereas I
had arrived at three research questions that I wanted to focus on for my research, as I
worked through my notes, it became obvious to me that a missing category was how my
participants thought about innovation in the first place. Respondents also addressed in
their interviews the ways in which they defined innovation in their global context and,
also, the importance of creating a culture of innovation to be successful as an
organization. Because this was new and not planned, I added another results chapter that
is introductory in nature and addresses these unexpected ideas that arose in my
interviews. While these unexpected themes that emerged in my interviews did not
necessarily speak to my three research questions, they ultimately reflected some of the
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preliminary literature review that I engaged in, including working definitions and
conceptualizations of innovation.
Finally, while I began this research with a specific interest in “serving the
underserved,” due to the snowball sampling technique that I employed along with the
range of firms from which I ultimately was able to gather interviews, the final focus of
my research ended up being much broader than originally anticipated. That is, I did not
just focus on how innovations travel from one part of the world to another - for example,
from underserved countries to developed world markets. Thus, while I began with a
specific interest on “reverse innovation,” what I ultimately adopted was a broader look at
innovation, which, in the end, seems more reflective of the various kinds of innovation
strategies employed by multinational organizations in global contexts.

Table 2: Firm Characteristics

	
  

Pharmaceuticals

Technology

Other - Academic

Percent of
Respondents

40%

40%

20%

Business Areas of
Focus

Pharmaceutical
consulting,
biosimilars, IBS,
ophthalmic
products, respiratory
condition products,
vaccines, central
nervous system
products

Hardware, software,
digital production
solutions, financial
technology
solutions, wireless
technologies,
healthcare imaging
technologies,
electronics

Globalization,
innovation,
execution, strategy,
management,
organizational
behavior

Size

500 – 80,000
employees

100 – 400,000
employees

n/a

27	
  

	
  

28	
  

Chapter 4: Results – Conceptualizations of Global Innovation
The overarching question that has guided my research is: How do global leaders
manage innovation across multi-cultural contexts? My interviewees addressed this at
various points in my interviews with them, oftentimes circling back to three key topics:
their own definitions of innovation, the significance of creating a culture of innovation,
and importance of building certain kinds of structures to cultivate innovation in their
organizations. These were central issues in their minds that were raised in response to my
broader question about leading and managing innovation in a global arena. Addressing
these specific issues seemed to precede or provide the necessary grounding to my more
nuanced questions regarding managing local and global tensions, altering one’s
leadership style, and pursuing local partnerships. Therefore, I begin with these three
themes that emerged as central in this first findings chapter.
Looking across interviewer responses, definitions of innovation seemed to span a
number of themes. According to my interviewees, innovation is about more than just the
products and services that a firm provides to a consumer base. Innovation can also be
about distribution and selling. The key to success, is determining what aspects of
innovation should be done where – there are certain aspects of innovation that can be
centralized and standardized across regions, while other aspects require a more localized
view.
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Definitions of Innovation
Definitions of innovation varied across my two industries of interest. Professionals in
the technology field explained that innovation was the development and delivery of new
value for customers and, further, that it involved the “organic” creation of new
technological products and services. Respondents explained that the crux of innovation
for any technology-driven organization is finding the intersection between what is
technically possible for a company and what consumers value most. Under this theme of
delivering new value to customers, innovation in the technology world often signifies
creating a new capability or component that did not previously exist.
Interviewees of technology firms also spoke to the notion of “organic ideation” or
the process of forming ideas There was a sense among interviewees that some of the
greatest ideas are not scheduled, but rather, that they were stumbled upon. As participants
described, after a firm’s initial success with a particular innovation, the process of
innovation often tends to shift; rather than searching for the next best idea, the process
instead begins to revolve around adapting current technologies to new settings and
improving upon that current successful technology. One of my interviewees pointed to
the iPod as an example of an initial great product, from which other products, such as the
iPhone, were then able to develop. Thus, innovation can occur in an organic fashion – by
altering and reworking products over time to fit a new setting and through business model
alterations that continue to utilize that same great initial idea.
In my interviews with leaders in the pharmaceutical industry, the definitions of
innovation differed from their technology counterparts in several respects. First,
interviewees from the pharmaceutical sector supported the notion that their job in
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innovating was to create new pathways to address existing problems; thus, there was less
discussion of solving unknown problems, as was the case in the technology space.
Innovation, for these individuals, focused on understanding current problems in medicine
and in health, and then finding new ways to address these issues.
However, similar to those in the technology world, managers of pharmaceutical
firms argued that innovation could go beyond the product itself; business model
innovation was also integral to successfully innovating in the field of pharmaceuticals.
Innovation in a business model could mean taking successful products to markets in
which they had yet to participate or in slightly altering a successful product to transform
it into an innovative product in an already established market. One manager spoke in
particular about her experience bringing an infant formula to two very different markets.
While the formula itself did not change when shifting markets, the quantity in which the
product was sold as well as the price point were adapted to fit the needs of the new
market.
Across all of my interviews I found that interviewees stressed the importance of
moving beyond a view of innovation that is solely product-driven. Yes, it is important to
create new technologies and new formulas to address pressing issues in our current
society, but products themselves can only do so much if the business model is not
innovative as well. As we delve further into the data, we will see this theme emerge again
and again – it seems that innovation can and should occur at every stage in a business in
order for a firm to be successful and remain at the forefront of its field.
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Creating an Organizational Culture of Innovation
In addition to discussing their own definitions of innovation, participants
described a general and pressing need, which was to establish a culture of innovation
across cultural contexts within a firm. They discussed how to create such a culture that
fostered ideation, and in so doing, a number of important themes emerged.
Among my respondents from the technology field, there was some disagreement as to
how and whether firms should truly take on the risks associated with being explicitly
innovative. The majority of my respondents, however, favored a more risk-prone culture
and argued for the creation of explicit goals and programs around innovation that could
ultimately increase patents and filings. These respondents advocated strongly for creating
a culture of innovation – that is, creating shared norms that support the idea that peoples’
new ideas are highly valued. This kind of culture, they argued, can jumpstart and
incentivize the innovation process. In an effort to promote an innovative culture, one firm
instituted a reward and recognition program whereby individuals who shared their
inventions and received approval for them could be part of a team that brought their ideas
to inception. In addition, it set aside a specific period of time every month for employees
to innovate and even provided them with coffee and pizza to show appreciation for their
ideas.
Other firms in the technology field did not put an equivalent emphasis on
innovation, but instead were more conservative with their approach to innovation.
Leaders of these firms underscored the importance of being fiscally responsible and
promoting stable innovation. Rather than taking large risks and building out radical
products, these firms followed a more risk-averse business model that focused on

	
  

32	
  

stability rather than originality.
While there was a dichotomy between risk-loving and risk-averse firms that arose
across my interviews with leaders in the technology field, most technology managers
stressed the importance of information-sharing across an organization as a key factor in
successfully fostering an innovative culture. According to participants, keeping people
informed and involved in the ideation process will lead to stronger, more effective, and
ground-breaking ideas. One manager noted that he encouraged his coworkers to grab a
beer with one another and become friends; he emphasized that socializing within the
larger organization would cultivate relationships and help create a community where
people felt comfortable bouncing ideas off of each other. Most interviewees also noted
that in order for individuals to feel comfortable in the ideation process and have a clear
understanding of their roles, it was important to streamline and assemble a set of common
objectives across the larger organization. This way, individuals would be more apt to
share ideas with other employees who they felt were working toward a common goal
with them.
According to my interviews, there are clear differences in how a manager in the
technology industry versus the pharmaceutical industry creates a culture of innovation. In
pharmaceuticals, idea management and maintaining an innovation culture over extended
periods of time is key due to the extended innovation lifecycle required to develop a
product. While in the technology space an innovation from its birth takes on average 2.5
months to 2 years (Thomke and Reinertsen, 2012) to get to market, in pharmaceuticals,
an idea has to be nurtured on average about 12 years before it is even accessible to
patients (California Biomedical Research Association) . Thus, the management of ideas
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and an innovative culture is integral to turning an idea into a therapy; this is especially
trying as employees must be motivated to engage in the work or a single objective for
years on end. A number of participants in my study referenced the length of the
innovation lifecycle in pharmaceuticals and how it affected the way leaders of
organizations managed a given organization’s culture. My interviewees also stressed that
the risk profile of a given pharmaceutical company tends to shift over the course of its
innovation lifecycle.
In particular, participants from the pharmaceutical industry stressed the
importance of creating a corporate culture of innovation during the early-stages, when
pharmaceutical companies are just beginning to develop new ideas and technologies.
When pharmaceutical companies are in their early stages of growth, managers and
employees must understand that innovation is messy and not always linear and further,
that the pathway forward is generally both incredibly difficult to predict, lengthy, and
fraught with extreme levels of uncertainty. Given these particular challenges associated
with this industry, respondents explained that the ability to create an organizational
culture that encourages risk-taking and exploring new ideas often comes from the
example that leaders set within their organizations from the start. As they explained,
leaders in this sector must be fearless, passionate, and work with a certain conviction.
Words like “commitment,” “dedication,” and “focus,” were used to describe global
leaders who were able to take the ideas of their employees and run with them into the
daunting early stages of drug development.
Successful managers in the pharmaceutical industry were described as fostering a
culture of innovation through two-way dialogue, participation, and urgency within their
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organization, similar to that which managers in the technology world raised as integral
aspects to an innovative culture. Managers of pharmaceuticals also noted the importance
of appreciating different styles of thinking to foster ideation; certain individuals generate
ideas more effectively by working quietly on their own, while others prefer to bounce
ideas off of others. Irrespective of where the idea originates, in order to create a corporate
culture of inclusion and one that values innovation from all different types of individuals,
managers must account for these differences in work and thinking styles. One manager
suggested that in meetings they allowed employees to think quietly on their own about an
idea for a certain period of time, and then gave them time to share these ideas with other
members of the group, thus addressing both types of individuals’ learning and thinking
styles.
A common concern that arose from my interviews with leaders in the
pharmaceutical industry as opposed to those in the technology space was the reality of a
shifting risk profile within an organization as it matures. Once a product is
commercialized and an organization achieves a certain level of success, the small and
innovative company that it once was becomes a new company – one that often loses track
of its discoverable abilities and one in which innovation can grind to a halt. The
organization may shift from one that was a growth engine with a single-minded focus on
product discovery, approval, and launch, to a mature and successful company that may
want to preserve what it has created. Thus, it may become resistant over time to the
culture of innovation it tried to cultivate early on.
According to my interviewees, this desire for preservation of past achievements
can be the greatest detriment to innovation and can contribute to a loss of focus and,
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ultimately, if not checked, a loss of market share. After a firm spends considerable time
and energy on creativity and taking risks, the comfort of success is tempting. In addition,
growth must be preserved in order to maintain current channels of investments and to
stay ahead of competition. Product commercialization requires entirely new areas of
business that did not exist during the innovation stage of the business. Some companies
attempt to combat this reality and maintain both the innovative arm and the commercial
arm of the organization. As some of my respondents suggested, after reaching successful
commercialization with a given product, the key to remaining innovative and mitigating
the change in an organization’s risk profile is to cultivate a string of other new products
in the pipeline. One leader in particular believed that his company could bridge this gap
between innovation and commercialization because of the innovative platform that his
company boasts; he believed that by harvesting this innovative platform for multiple
drugs, his company could continue to innovate into the foreseeable future,
commercializing products for which the company’s current infrastructure allowed.
Across both sectors, then, the similarities were most obvious when comparing the
responses of managers who discussed the significance and processes for cultivating a
culture of innovation during the early stages of the discovery or product development
process. However, given the longer life cycle of pharmaceutical products and the relative
uncertainty and complexity of the science involved, sustaining this momentum over time
among employees seemed to require additional effort, including incentive structures and
systems that were more heavily managed in the pharmaceutical companies than in the
technology companies. Overall, however, the prevailing wisdom appeared to be that a
culture of innovation was a necessary condition for success and for sustainability in the

	
  

36	
  

marketplace. Even those who did not advocate strongly for this kind of culture or who
erred on the risk adverse side due to financial constraints or pressures toward
conservation noted the significance of ideation and a culture of innovation, particularly
early on.

Creating an Organizational Structure to Encourage Innovation
Technology. My technology global managers described the importance of
organizational structures in and across their firms in order to encourage and cultivate a
fertile environment for global innovation. In technology, respondents discussed the need
to purposely create separate kinds of subunits within firms to enable global innovation,
whereas in pharmaceuticals, the discussion was more about the kinds of overall type and
size of companies that were more focused on innovation versus commercialization.
In order to cultivate an organizational environment that fosters innovation across
country contexts, managers in the technology field underscored the importance of
creating an organizational structure that would enable rather than stifle innovation. For
these managers, connecting to the outside world and the customer in particular was seen
as vital to the creation of new and innovative technologies. In addition, mitigating the
risks that come along with innovation was imperative. As such, many of my participants
employed a similar strategy to connecting with markets in order to recognize areas of
emerging value – this strategy involved the creation of small teams or a single
autonomous innovative unit whose sole focus was to innovate beyond the technologies
the company had already marketed and operationalized.
The idea behind autonomous business units is to maximize innovative capabilities
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within a firm while reducing risk for the larger organization. In one firm that creates
technological financial services products for customers, the manager I spoke to operated
his innovation business unit “like a start-up.” The team was funded separately from the
larger organization and was comprised of a group of diverse individuals with varying
backgrounds in an effort to generate ideas that were fundamentally different from what
the larger organization had already created. Establishing this separate business unit
structure seemed to help address one of the issues that frequently came up in my
discussions with managers – innovating within established businesses. A number of
managers spoke to the tension of innovating within well-established businesses. As they
described, oftentimes, c-suite (senior level) executives shy away from innovation because
it feels risky to them and could disrupt an already successful business that is the driver of
its profits. For example, one respondent explained that hiring individuals who understood
the local markets to lead these smaller business units would create a more efficient and
innovative business model strategy. In this way, executives in the larger organization
could continue to focus on strategic initiatives for the firm while the smaller business unit
could focus on the creation of new value through innovative product development.
The autonomous innovation business unit structure could isolate innovative ideas
and projects from the larger business unit, thereby creating a safe space for building and
testing concepts without inflicting potential damage on the mother brand. Employing a
separate business unit solely focused on innovation can allow a company to take risks
without harming the reputation or success of the larger organization. Thus, for my
technology respondents, it was often the case that their companies found structural
solutions to the problem of cultivating innovation.
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Beyond creating a separate business unit for innovation, the actual operations and
leadership of the unit also become critical to success. Managers underscored the
importance of remaining connected with the larger organization by way of the innovation
arm’s management in order to retain funding and legitimacy. Many of my interviewees
called for managers of the smaller business unit to operate as the liaison between the
larger organization and the innovative arm. They could do this through their own liaison
roles and/or through communication structures such as regular meetings that enabled
them to update those in senior level positions in the established base of the firm as to the
progress they were making and/or the resources they needed.
Further, to maintain a certain degree of autonomy, the technology interviewees
told me that the manager should take on what one person described as a “bicultural
approach.” This sort of leadership would include transferring the larger organization’s
ideals to the smaller autonomous unit to serve as guiding principles. Simultaneously, the
manager must also continuously foster an entrepreneurial culture within the autonomous
unit. In nurturing this liaison, the manager of the smaller innovative unit should report
directly to the CEO or a c-suite level manager of the larger organization. This
relationship will not only keep the flow of communication open between these separate
units, but will also ensure that the innovative unit receives adequate funding, and that
executives remain excited about the innovation that is happening apart from the larger
organization.
Many technology respondents saw an autonomous innovation unit, which may
reside in different geographic regions, as an adequate solution to global innovation risk; it
was mutually beneficial to both the innovative side of the business and to the larger
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organization as a whole. While the innovative arm could remain alive and vibrant in
creating an entrepreneurial culture that encouraged risk-taking and idea generation, the
larger organization could maintain its trusted image without taking on the risk of
innovation, and while still claiming to be innovative. This sort of structure came up as an
ideal solution to convincing management to provide adequate funding for innovation,
particularly in established businesses.
In a similar vein, some of my technology interviewees believed that creating
numerous autonomous business units that each specialized in different regions would be
another way to create a successful structure for global innovation. These autonomous
teams would work with a specific consumer base in a given geographic region to
determine a need in the market and to assess market dynamics. They would speak with
customers, develop partnerships on the ground, and test out ideas. They could adapt and
create new technologies directly applicable to emerging value in a given region. In this
way, innovators would be closer to the market geographically and thus, would be able to
more successfully innovate for the needs of a particular market.
Other managers I interviewed in the technology field found that creating a single
global research and development center was more effective in the innovation process.
This R&D team would be comprised of individuals coming from varying cultural
backgrounds that brought together different experiences and views to create innovative
and groundbreaking ideas. Testing and labor-intensive work with the technologies would
then be undertaken in the markets for which these products were made. Their argument
was that concentrating the innovative function of an organization in one particular
location would allow for all of the brightest, most creative minds to work together and
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collaborate, rather than being scattered across the globe. This sort of collaborative and
diverse structure required a different sort of role for managers – one that focuses on
aligning a diverse set of individuals to come up with the ideas that effectively serve
actual market needs.
Many technology managers seemed to struggle with similar issues when leading
the innovative side of their businesses, whether as a subunit or larger R&D center. As the
interviewees explained, oftentimes, individuals involved in R&D are “super engineers” or
just want to create the next most original and groundbreaking idea. Managers agreed that
having a solely innovative culture was not enough to drive success. Product development
strategy could not just be centered on great path-breaking ideas; it needed to first and
foremost aim to fulfill specific consumer and market needs. Further, products should be
developed to serve the largest markets with the most commercial potential. For example,
one manager whose company creates radiology technology for consumers across the
globe spoke to the importance of developing products with commercial potential. He
stated that after assessing where the largest markets would be for his company’s
technology, products were then either adapted or developed from scratch to meet needs in
that given geography. If a specific feature or product would only be applicable in
Malaysia, for example, he said his firm was unlikely to prioritize the its development
because the commercial potential was much less than that which existed in American or
European markets.
Pharmaceuticals. My pharmaceutical interviewees seemed much less concerned
with the consumer-side of the business, and thus, creating autonomous units for
innovation was not an organizational strategy typically employed in the field according to
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my interviewees. According to managers I interviewed in pharmaceuticals, the trend in
pharmaceutical organizations is to centralize research and development centers, typically
in the United States or Europe, to address underlying science of the work in areas such as
chemistry.
This sort of organizational structure that is centralized rather than separate from
the larger organization or scattered in numerous locations can, in part, be attributed to the
location of information hubs. A number of participants stressed the importance of
locating the research and development where research universities and capital investment
are located. This way, R&D centers could have access to the most novel and forwardthinking scientific ideas and also to the capital necessary to fund their innovation
exploits.
One can point to a difference in the way a pharmaceutical company innovates
from its technology counterpart as an underlying reason behind this type of
organizational structure. Typically, a pharmaceutical company has a specific area of
expertise, a technology that it has developed, and a proprietary method of developing a
drug. One manager described the way in which pharmaceutical companies innovate as
“haphazard,” in that rather than solely relying on the needs of certain consumers,
companies tend to match their technologies and abilities to meet the biology of a certain
condition. Once a company has successfully developed one therapy, it will often
capitalize on its current technology and platform to target other diseases, keeping the
drug discovery engine running. In this way, innovation is central to the overall business
and would not run as effectively as an autonomous business unit. Further, because
companies tend to match their technologies to emerging health needs, it is less important

	
  

42	
  

to have a number of teams on the ground addressing local problems as it is to have
research and development individuals together in a concentrated location working
tirelessly to match a firm’s technologies to a particular disease.
Beyond the organizational structure within a firm itself as it relates to innovation,
my pharmaceutical interviewees also pointed to the size and stage of development of a
given organization as significant when analyzing the best organizational design to
generate ideas and to develop new drugs. While some participants supported the notion
that pharmaceutical companies could indeed operate both the innovative and commercial
side of their business simultaneously, others claimed that the reality of the industry is that
smaller pharmaceutical companies are oftentimes the engines for innovation, while
larger, later-stage companies tend to buy innovations from such firms and commercialize
them. Larger companies have the infrastructure and capacity to acquire products or
company — and then bring technologies to market. As such, these large established
companies will tend to identify an unmet need in the market that they would like to fill,
determine what smaller biopharmaceutical company is addressing this need, and then
bring the innovation in-house.
Following the acquisition of programs, technologies, or companies, these larger
pharmaceutical companies will often then add staff to the innovation project and build it
out to commercialization. Smaller companies, on the other hand, are more inclined and
able to innovate with a certain level of creativity and entrepreneurial spirit that is more
difficult to foster in well-established organizations. Pure innovation, according to many
of my pharmaceutical managers, truly stems from academic hubs like universities, and
these individuals tend to move to small companies, to receive early-stage funding to
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pursue their ideas. Smaller organizations take on large risk by nurturing their new
technologies from birth, whereas the structures and systems of larger pharmaceutical
organizations are generally designed for commercialization and so, are willing to pay a
premium to minimize the risk associated with innovation. 	
  
Comparing these two sets of respondents reveals some clear differences in how
managers of technology versus pharmaceutical companies tend to foster innovation
through the structures they put in place (or acquire) in their firms. In technology
companies, the focus was on creating protected spaces such as subunits charged with
coming up with new ideas that were intentionally separated from the larger firm or, in a
similar fashion, by creating a protected R&D center for that same purpose. In contrast, in
the pharmaceutical companies, while innovation was also highly valued, the
organizational structures were designed for the implementation or commercialization of
innovations, rather than, in general, the very earliest stages of idea generation. Instead,
therefore, larger organizations to appropriate other smaller firms that were themselves
already intact innovation incubation structures and then commercialize therapies from
there. In both cases, the structures – whether bought or made in-house – were designed to
protect spaces for the cultivation of innovation as well as minimize the risk that the larger
organization might face when straying from its core business in order to innovate.
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Chapter 5: Results - Serving Multiple Customer Needs
When participants commented on the challenges of serving multiple customer
needs, three tensions emerged that seemed to span the experiences of managers in both
technology and pharmaceutical industries. Although not all of my interviewees’
organizations operate in underserved markets, the themes regarding tensions they faced
seemed broadly applicable. These themes included concerns regarding a) the potential for
dilution of market position and brand, b) the ability to innovate in an efficient manner
globally, and c) an entrenched mindset within management that could stifle innovation.

Serving Multiple Customer Needs: Brand and Reputation
In the technology field, as is common in many other industries, one of the
challenges faced by managers is to protect the brand of an organization. When creating
an emerging technology, how do you balance addressing the largest market possible
without diluting brand or cannibalizing margins? In other words, a number of my
participants wrestled with the concern that new innovations might negatively impact the
sales of an existing product by inadvertently catering to existing consumers rather than
expanding to attract new consumers. As respondents explained, the challenge of
innovating is maintaining that core business with great brand equity or name value of a
brand, avoiding the alienation of customers, while also coming out with new products.
Some managers argued that to offset potential brand dilution due to their exploration into
different innovative solutions and products, firms could create a stratified line of products
with varying levels of features based on consumer need, thus gaining the largest possible
market traction. Firms could then price their products of varying sophistication at
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different levels so as to create an array of products for the various needs and levels of
affordability of consumers.
An example of a successful product differentiation to gain broad market traction is
General Electric’s (GE) Electrocardiogram (ECG). GE’s initial goal with the ECG was to
create a product for the needs of an underserved population in rural India. The ECG was
ultimately marketable on a global scale and adopted by developed countries; smaller
individual practices in developed markets purchased the machine due to its lower price
point (Immelt, Govindarajan, Trimble 2009). From there, GE adapted its ECG’s
capabilities and features to address a larger consumer market (Winter and Govindarajan,
2015). GE’s ECG ultimately branched into four different prototypes, which were sold at
different price points to varying consumers around the world (Govindarajan and Trimble,
2012).
In a similar vein, some managers in technology firms made the case that when
designing products to begin with, a firm should create innovations that could span
multiple geographies. One manager said that his best case scenario for innovation was
developing products suited for the developing world but also “good enough” and highly
sought after in the developed world, a technique that firms like GE have come to master.
Others opted to address issues of reputation dilution by launching an entirely separate
brand oriented toward the innovative side of the business. This way, the innovative brand
could have the funding and resources of the larger organization and would be marketed to
new customers, while also allowing the company to protect and preserve the quality of
the mother brand.
Still, even with these kinds of structural solutions, managers expressed concern
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over brand dilution with new technological innovations have led some companies to
innovate “safely.” In an effort to continue innovating but also mitigate risk, firms may
add incremental value to already successful products instead of seeding new lines of
products. This strategy could help keep a firm current, tailoring or updating products to
the needs of newer consumers, while also reducing the potential dangers associated with
more radical forms of innovation.
The pharmaceutical managers I interviewed were also concerned about dilution of
brand reputation but had a very different conception of brand from their technology
counterparts. While brands such as Apple and Oracle denote a certain reputation that
encourages (or dissuades) a customer from purchasing their product in the technology
world, pharmaceutical customers will not necessarily purchase a drug because a
particular firm made it. For pharmaceutical consumers, the importance of corporate brand
loyalty is overshadowed by the importance of whether or not regulators have given a drug
their stamp of approval.
According to my interviewees, the brand of each particular drug stands separate
from the brand of the larger organization; doctors and patients identify with a specific
product brand much more so than the company brand as a whole. Pharmaceutical
companies will spend extensive amounts of time and a great deal of capital in order to
create awareness for a particular drug; pharmaceutical companies move from product
brand to product brand. For each particular product brand, the timing and lifecycle of the
product is significant. Companies can extend the brand of a particular product by
carefully timing the release of a new product that is an improvement upon its
predecessor. The key here is to launch the improved product late enough in the previous
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product’s lifecycle so that it does not cannibalize sales, but early enough that a
competitor does not come out with an improvement sooner. Innovation then tends to
occur in an area where a firm has had prior success; pharmaceutical companies capitalize
on the successful brand of a particular product by developing new drugs that fall into a
similar therapeutic category and by tying new products to that successful and innovative
product. An example of the importance of a particular product brand is the ADHD
medication Ritalin, which is owned and produced by Shire. Individual consumers trust
and recognize the brand Ritalin, which is the brand for the individual product itself, but
are typically unfamiliar with the brand of the larger organization, Shire.
The company’s brand in the pharmaceutical industry is typically more important
for attracting employee talent and creating shareholder value than it may be for attracting
consumers who gravitate more toward the brands of isolated products. Still, it is possible
for pharmaceutical companies to build a certain degree of corporate brand loyalty across
products. Through different forms of Corporate Social Responsibility or by donating
drugs to a particular cause, for example, firms can demonstrate to consumers that they
operate their business responsibly and so, build overall brand loyalty associated with a
particular company.
Pricing decisions across international boundaries can also serve to hurt or improve
a firm’s reputation. According to my pharmaceutical interviewees, upholding a
company’s brand is even more challenging across international markets because each
market has its own idiosyncrasies. Oftentimes, this challenge is dealt with through
pricing; negotiations with healthcare insurers or governments (depending on the country)
affect the resulting price and ultimately, the brand of the firm as well. While low prices
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for a particular drug in one market may bring about reduced profits, company brand is
often improved by a given firm providing a product at low or no cost to those who cannot
afford the cost of a particular drug. In this way, by building loyalty for the firm, a
pharmaceutical company may offset the reputational risk that it might otherwise incur
when engaging launching innovative extensions to its brand.

Serving Multiple Customer Needs: Global vs. Local Trade-off
“I find that some of the best innovations are locally driven,” said one of my
technology interviewees when discussing the difficulties of balancing efficiency and
customization when innovating for a global market. Many of my interviewees,
particularly from the technology field, struggled with the desire to remain efficient and
streamline production while also using local knowledge to truly capture a specific
consumer market. While centering innovation in one location can provide certain
efficiencies for firms, particularly in production, centralization means giving up
customization . Managers described various techniques for addressing this global vs.
local tension; the location of each firm on this spectrum of global vs. local control was
highly variable amongst my interviewees.
Some technology managers stressed the importance of efficiency over creating
tailored products. These firms tended to develop products in one central location and then
would customize the commercial side of production as a way of catering to different
markets. Thus, the actual product did not change across borders, but rather, the
messaging, price point, and sales method, were tailored based on geography. One
manager, whose firm develops healthcare technology products, discussed how different
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consumers had varying expectations depending on geography. He found that doctors in
private practices looked for efficiency, cost-effectiveness, and time-efficiency. In
contrast, healthcare markets such as those in Europe and Asia that are not privatized,
were home to doctors who were more focused on the quality of care rather than increased
productivity. As such, he found that tailoring the messaging and sales method depending
on the consumer base was incredibly important for attaining considerable market traction.
Other technology firms my interviewees spoke about fell in the middle of the
global-local spectrum. My interviewees explained that this allowed them to remain
efficient and capitalize on economies of scale but also create relevant products. These
middle-spectrum firms would typically use a generic base technology developed to span
multiple geographies, and then would leverage local relationships and development labs
to develop out the product for a specific consumer base. In a similar vein, some managers
I spoke to established centralized R&D centers, stripped products down to their simplest
form, and then worked hand-in-hand with end users, and through various iterations,
developed features reversely for their needs. Managers noted that this method helped to
account for technical requirements that must sometimes vary depending on cultural and
regulatory environments.
On the other end of the spectrum were managers I interviewed in technology who
were staunch supporters of localization and believed that teams that were geographically
closer to the consumer could create the best products. For these firms, local idea
generation was valued more than cost-efficiency. Managers of these firms said that true
innovation does not come from someone sitting in an office in the US or Europe. Rather,
it comes from “someone under a mango tree in rural Uganda, really absorbing the local
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needs and culture.” This difference in value placed on localization in a particular firm
could in part be due to the backgrounds of the managers and leaders themselves. I found
that managers who were more personally involved in or conscious of local community
needs tended to instill these values in the corporate culture of their firm. In contrast,
leaders who seemed more preoccupied with efficiency and productivity might be more
inclined to stress centralization of operations within the firms that they managed.
As these technology managers explained, their firms were organized such that the
heavy lifting in idea generation happened in the field. Managers used teams of skilled
individuals to work with the communities for whom a product was being developed.
These teams listened to the potential customers, bounced ideas off of them, and once a
tailored solution was created, would adapt it based on client feedback and experiences.
According to these individuals, at the heart of building relevant products for consumers is
having deep local knowledge. While maintaining a heavy local footprint was vital to
these managers, their role was to also ensure that the firm’s innovative arm was not
“reinventing the wheel;” they also helped to create a space for knowledge sharing, and
allowed for the provision of global expertise to various local teams. Other interviewees
described using different strategies for product development depending on the product
itself. Thus, amongst my interviewees, there was not consensus on one best strategy, but
rather, a set of possible approaches that would help them be cost-effective in their
operations while simultaneously providing relevant products to the client.
The global versus local dichotomy in the pharmaceutical world is conceptualized
very differently from the technology space. Products themselves do not tend to change
drastically depending on their geography. This lack of product customization in
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pharmaceuticals can in large part be attributed to the fact that most diseases do not
fundamentally change in a patient depending on location. Some do, but the underlying
biology and chemistry of human beings does not, in contrast to the very different needs
seen in the technology field across geographies.
In lieu of product adaptation, pharmaceutical managers tend to focus their efforts
toward business model innovation on the commercial side. These managers stressed that
innovation was not just about product development, but rather, about the distribution,
selling, and advertising of developed products. For example, varying regulatory
environments allow for products to be positioned differently depending on a given
market. Biotechnology companies work through negotiations with regulators to enable
their product(s) to treat (according to the label) as many indications as possible. In this
way, the same drug can be positioned to treat different ailments depending on regulatory
environments. Managers of pharmaceutical firms also pointed to the importance of
innovation in the delivery of a product. Drugs come in all different forms and can be
administered orally, through injection, inhalation, or as topical treatments. If a medication
is brought to market, but the form of administration is not acceptable to the market it is
trying to serve, the product may not be successful. Further, packaging and advertising
preferences for pharmaceuticals may also vary by location. Different cultures may find
certain types of advertising more appropriate than others – for example, according to one
of my respondents, Japan and the Middle East tend to prefer more conservative
advertising as compared to their American counterparts. Therefore, tailoring this aspect
of the product can help a product gain traction in a particular market.
My pharmaceutical interviewees also described how sales force adaptation is

	
  

52	
  

another way that companies can customize and innovate around the commercial side of a
product. For example, in North America and Western Europe, the role of the sales force
is fundamentally educational – they work with physicians to explain benefits and side
effects of a given product. In other parts of the world like China, India, and Brazil, sales
are more transactional in nature, as representatives focus on selling the product to the
physician rather than educating them. In this way, hiring and training sales forces based
on geography can be effective in customizing a product’s image to a particular consumer
base.
According to pharmaceutical respondents, pricing is another way in which firms
innovate on the commercial side for a specific consumer base. In negotiations with health
insurers or governments (depending on the location), pharmaceutical companies will vary
the price of their products based on local needs for the product, ability to pay, and capital
required to recuperate R&D costs. In some cases, if negotiations do not reach a pricing
outcome that is deemed adequate (covering manufacturing costs, for example), then the
product may not be launched there at all. In this way, an appropriate pricing strategy may
allow for a broader acceptance and availability of this innovation on a global scale.
However, if pricing negotiations are unsuccessful, the innovation may be constrained in
its availability, limiting its potential benefit to patients.

Serving Multiple Customer Needs: Entrenched Mindset
A third tension that arose during innovation particularly for my technology
interviewees was managing the established business and what they described as an
entrenched mindset of management, while continuing to foster innovation. This tension
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seemed to be less of a concern for pharmaceutical managers for whom the development
and acquisition of new drugs seemed to always be central to the business model.
In technology companies, interviewees pointed to the delicate balance that leaders
had to manage between protecting an organization’s previous successes while remaining
at the forefront of the industry in innovation. This tension arose in large part due to the
differences in cognitive thinking between c-suite executives and that of the innovators in
the business. According to respondents, in larger, more established companies, the
majority of employees, and in particular, executives, wanted to protect the status quo;
moving away from the norm and being truly innovative entailed entering the “fight of
your life with management.” Established companies, respondents said, tended to
eventually fall into a cycle of incremental innovation rather than investing in new
technology.
As my respondents explained, an entrenched mindset within management is an
obstacle that can lead to insufficient funding of radical innovation; executives tend to
focus heavily on retaining market share and current customers, which can come at the
expense of generating new income and new ideas. The monetary and reputational value
that a technology could bring to the firm was of utmost importance to executives. Tasked
with delivering visible results to shareholders, high-level management is often concerned
with what would happen to the profit model if a new idea were brought to the platform.
In this way, as my interviewees explained, leaders will often organize their
innovation strategy around financial quarterly reporting and shy away from radical
innovation that could potentially harm current profits or cannibalize margins on already
successful products. However, in order to retain market share, a number of my
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interviewees pointed to the importance of investing in new opportunities and developing
products that were truly original. Innovators within an organization seemed to starkly
contrast the risk-averse and entrenched mindsets of managers; they were excited about
creating technologies that were “cool” or “exciting,” but not necessarily those that would
have certain value for consumers.
To address this disparity in cognitive methods of thinking about innovation, some
managers advocated for a focus on the business model of the technology itself. A
manager’s role was thus to align the value they saw in the industry with the value that
could be actualized by the company given its structure, brand, and infrastructure. This
meant paying careful attention to the operations behind innovating – who would manage
the innovation, how would a flow of communication remain open between innovators
and executives, how much risk the firm was willing to take on and so on. These sorts of
questions would allow leaders to ensure that decisions about innovation were not being
made based on personality, impulse, or what was politically or financially convenient.
While doing this, managers also had to be sure that they were not simultaneously overconstraining the innovators in their company. Accordingly, respondents suggested that
innovation should not be implemented purely on the basis of cost and reputation. Time
constraints and generating short-term shareholder value should take a backseat to idea
generation and innovation itself.

Serving Multiple Customer Needs: Innovating for a Specific Consumer Base
While respondents in both sectors emphasized the need to manage their
established brands and innovate efficiently on a global scale, managers also addressed the
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challenges that arose when innovating for a specific consumer base. The tensions
inherent in addressing the specific needs of consumers varied across the technology and
pharmaceutical industries. Thus, managers in these fields had different ideas and methods
about how best to develop relevant products for consumers.
A trend that arose amongst managers, particularly in the technology sector, was to
stress the importance of communication in creating the best possible products for
consumers. This trend is something that we will delve into further in Chapter 7 when we
examine the importance of local relationships, but we will touch on it briefly in this
chapter as it pertains to innovating for a specific consumer base.
Technology managers insisted on the practicality of dialogue in the innovation
process. Keeping an open flow of communication with different groups such as clients,
analysts, scholars, reporters, and other influencers, seemed central to best understand the
technology trends within the industry. Additionally, remaining up-to-date on recent
technological findings seemed to help these firms maintain a breadth of understanding for
scientific and academic knowledge. After dialoguing with key influencers, managers
suggested returning to the drawing board with ideas, and then determining what
innovations, within the capabilities of a firm, were actually possible. The dialogue does
not stop at the ideation step in the process. Rather, once a product has been developed,
many of my respondents recalled using beta releases and collecting customer data and
feedback to adapt the product to better fit a needs gap in the market.
For pharmaceutical managers, the trend amongst my respondents when innovating
for a specific consumer base revolved around certain motivations that dictated the
diseases (indications) that a firm might target. Important drivers for the selection of a
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specific indication included: clinical trials, competition, need, and previous experience as
a company. As my interviewees explained, there are numerous diseases that are similar,
and thus, a company’s selection criteria for the disease has as much to do with its
organizational strategy as it does with the disease itself. When determining a need in the
market and also when developing a technology itself, pharmaceutical managers also
stressed the importance of dialogue.
Similar to dialogue in the technology space, when innovating, interviewees
stressed that dialogue in the pharmaceutical world needs to focus in part on the customer
– in this case, on the patient or physician. When patients have a particular need,
physicians can help explain to a company the real symptoms that a drug should address,
and then a company can innovate to address these symptoms. However, pharmaceutical
researchers and managers can also determine a needs gap or jumpstart the creation of a
new drug through communication with academic scientists. Staying informed on the
findings of academic scientists (who are working outside the company itself) and then
capitalizing on potential partnerships and collaborations can help pharmaceutical
companies remain at the forefront of the industry, addressing needs in the market with
new and innovative science.
Some pharmaceutical companies attribute so much value to this communication
with academic scientists that they actually sponsor research at universities. In return for a
financial investment, a company might receive rights to be informed first of data from a
study, giving the company a jumpstart on the competition. This sort of academic
research, according to participants, varies from that which can be found on the R&D side
of a given pharmaceutical company. While pharmaceutical company research is
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constrained by the company’s goals and is highly targeted, academic research is not
constrained to making a particular medicine. Rather, researchers can address fundamental
scientific questions that can, in turn, lead to entirely new areas of applied and basic
understandings in the field.
Beyond determining a need in the marketplace, pharmaceutical interviewees
reported that their firms had similar processes for innovating around a particular gap.
Typically, a pharmaceutical company has a specific area of expertise or a technology that
they have developed in a certain scientific area along with a proprietary method of
developing a drug to treat a target. Once a need is identified in the market, companies
then determine if and how they can capitalize on their expertise to make an improvement
over the current standard of care. If the company believes it can address the needs gap
given its capabilities, it will start by targeting a narrow set of diseases within that needs
gap. Starting out with a narrow scope allows companies to more easily show early proof
of concept, which, in turn, can help it raise capital for clinical trials. This capital can also
eventually be used to expand the company and the product suite to address other diseases
within the needs gap identified.
In sum, both technology and pharmaceutical company global managers stressed
the importance of dialogue to address a particular needs gap in the market. However, my
interviews show that in the context of the marketplace and differing industries, global
managers in technology and pharmaceuticals implement different processes to innovate
around consumer needs.

	
  

58	
  

Table 3: Serving Multiple Consumer Needs
Research Question 1:
Is there a tension between innovating to meet the needs of multiple consumers across
geographic borders versus maintaining brand reputation worldwide; if so, how would
these be described?
Pharmaceuticals

Technology

Major Themes
Maintaining Global Brand
and Reputation

Global vs. Local Trade-off

Entrenched Mindset

Innovating for Specific
Consumer Base

	
  

• Brand often exists for
individual drugs more
prominently than for
entire company
• Organization’s brand
can, however, be
positively impacted by
CSR and fair pricing
strategies
• Operational efficiencies
are critical to consider
• Products are not typically
adapted; commercial side
may be tailored via
marketing, sales force,
administration, pricing

• Develop products with
the ability to span
multiple geographies
• Varying features and
pricing strategies for
different levels of
affordability

• Prior organizational
success and size can be
barrier to change
innovation

• Executives’ desire to
protect status quo versus
encouraging environment
for innovation

• Importance of external
communication –with
consumers and academic
hubs

• Importance of internal
communication

Spectrum of Views:
• Cost efficiency >
adaptation and tailored
solutions – centralize
development, alter
commercialization
• Middle ground –
centralize R&D, adapt
product features and
commercialization
• Localization > efficiency
– teams on the ground,
work directly with endusers
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Chapter 6: Results - Global Multi-Cultural Leadership
This study also focused on the question of, what kinds of tensions do managers
involved in global innovation strategies face in terms of adapting their own personal
leadership style as they cross global market cultures? When responding to this question,
participants told me stories about how they adapted their own personal leadership style to
suit the local culture they were working in or crossing into. Looking across these stories,
major themes emerged and, for the most part, these did not differ significantly by sector.
In both sectors, managers found that interacting with people from different
backgrounds and cultures was a necessity and an everyday task that they attributed to the
kinds of roles they held as global leaders of multinational corporations. Further, as
explained in Chapter 4, for many of my participants, staffing individuals in local markets
for whom products are being developed (and sold) is critical to the production of relevant
products for consumers. Therefore, they need to manage these individuals who may come
from very different cultures. Beyond improving one’s own leadership capacity for
managing a diverse group of employees, adapting management styles across cultural
boundaries was also mentioned as extremely important as these managers engaged in
business negotiations in different geographies.
In Chapter 7, I examine how local partnerships play an important role in the
innovation process. In this chapter, however, the focus is primarily on how mastering the
art of management across borders was critical to the success of my respondents as
leaders.
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Time Commitment
One theme that arose for my participants was the importance of time commitment
toward understanding the varying backgrounds of employees. According to managers in
both sectors, it makes good business sense for leaders to spend time with the individuals
who are most closely connected to the end users, particularly those who operate in or are
from a market different from the manager’s home market.
One respondent pointed to this commitment to understanding other cultures as a
fundamental driver of her success; she claimed that she had been successful in her career
because she had spent significant time in the territories in which her company worked
and adjusted her leadership and communication style as she traveled across countries. As
she explained to me, once you understand a particular culture, you can manage people
differently on the ground through different incentives, compensation, and forms of
motivation. Specifically, variation in how people from different nationalities prefer to be
managed involved how different cultures view authority and how they view gender
differences. As my respondents emphasized, every geographic region is different.

Active Listening
While business models and processes can be put in place to facilitate good
leadership, according to my participants, an agile leader is one who is able to create an
inclusive culture. In doing so, participants in both industries stressed the importance of
careful, active listening as critical to effective leadership. As my respondents explained,
if employees know that a leader will listen to them without judgment, then leaders will be
able to create a more open environment for innovation. Additionally, in listening to
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employees and understanding their knowledge, values, and abilities, leaders will be able
to better adapt their expectations and requirements accordingly. One manager noted that
some of her best conversations with employees were in informal settings where she could
more easily listen and communicate with her employees. Her ability to effectively
demonstrate her capacity to listen created an environment in which her employees felt
comfortable coming to her with issues or ideas. More generally, interviewees were
cognizant of the intersectionality of identities and communication styles, such as the
degree of assertiveness or confrontation when expressing one’s ideas.

Common Corporate Culture
Although adaptability, according to respondents, is critical to effective leadership
across borders, the maintenance of a common corporate culture was also emphasized in
my interviews; this common culture was described as critical to remaining a cohesive and
integrated organization. According to one manager, leaders must instill a common
corporate culture, while remaining accommodating and recognizing multiple cultural
contexts of employees . Leaders might synchronize timelines, company strategies, and
overall objectives across borders. But, at the same time, it was clear that maintaining
strong knowledge of cultural expectations so as to better lead and work with different
country cultures was paramount. Another manager observed that while he was respectful
of the various cultures of his employees, he maintained the same basic principles of open
communication, clear goals, and mutual respect – no matter in what geography he
operated in.
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Relying on Local Leadership
When managing across borders, a number of participants noted the importance of
capitalizing on local partnerships. Although we will discuss local partnerships further in
the next chapter as it pertains to innovation in particular, my respondents emphasized the
importance of relying on local leadership so as to better understand local and cultural
expectations in a given geographic location. One manager noted that when working
overseas he tried to bring as few American cultural expectations as possible with him.
Further, through the guidance of local leaders, he was able to better adapt to the beliefs
and values unique to a particular geographic region.
Managers across both industries valued similar attributes in successful leaders of
transnational innovation strategies. These attributes introduced by respondents included
time commitment to understanding different cultures, active listening to individuals
within an organization to create a corporate environment of trust, maintaining a common
corporate culture across borders, and capitalizing on local partnerships to better
understand the varying cultures that comprise the makeup of an organization. In each of
my interviews, managers placed significant value on their ability to adapt to different
cultural needs as a key contributor to their success as leaders. In sum, as one of my
interviewers aptly stated, the art of management is “managing people the way that they
need to be managed, not necessarily the way that it is easiest for you.”
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Table 4: Global Multi-Cultural Leadership
Research Question 2:
What kinds of tensions do managers involved in global innovation strategies face in
terms of adapting their own personal leadership styles as they cross market cultures?
Pharmaceuticals and Technology
Major Themes
Significant Time Commitment

• Face-to-face interactions improve
internal organizational trust, fosters idea
flow

Leaders as Active Listeners

• Create a better understanding of
linguistic, social, cultural differences
that exist

Maintenance of Common Organizational
Culture

• Consistent standards and values
strengthens unifies organization as a
whole, even while operating across
country boundaries/cultures

Relying on Local Leadership

• Local leadership helps improve
understanding of local and cultural
expectations of geographic regions
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Chapter 7: Results - Partnerships
The third question that I sought to answer through my interviews with managers
was how local partnerships were employed in the implementation of their innovation
strategies. Specifically, my question was: to what extent do managers use local partners
to implement their global innovation strategies? Are there tensions associated with doing
so? In particular, how does the firm protect intellectual property when engaging with
local partners? Respondents from both the technology and pharmaceutical industries
placed significant value on the role of local partners as both informants and business
representatives. However, they were also wary of the intellectual property risks that are
associated with partnering. Managers differed in their strategies to mitigate this notable
risk.

Partnerships: Benefits and Roles
Participants across both sectors discussed how the local partnerships enabled them
to assess different market needs; the focus, however, varied. In pharmaceuticals,
discussions centered around the ability of a global firm to broadly apply a technology it
had developed to various markets. In contrast, in technology, innovations were not
limited by a certain formula but rather, by the company’s own capacity and infrastructure
to address global market needs. In addition, respondents in both technology and
pharmaceuticals discussed how local partnerships served different roles in their
management of innovation—but this too differed by sector. Finally, participants
discussed the importance of intellectual property and its relationship to local partnerships.
In the pharmaceutical space, unmet needs are massive: many diseases have yet to
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be cured, individuals are living longer lives and thus need medicines to help them
continue to live beyond life expectancy, global interaction has facilitated the spread of
disease, and the quality of life for a patient can always be improved. Further, incredible
ideas and scientific discoveries exist within the pharmaceutical industry. The tension in
pharmaceuticals is the matching of a great scientific technology with an unmet need that
will allow technology to have the largest impact possible. A critical aspect to success in
different geographies in order to understand such needs and to implement solutions is
partnering with the right local entities. From the start, partnerships can help companies
better understand a given market, the needs there, the competition, drug approval
processes, reimbursement schemes, the regulatory path, and commercialization methods.
With these local partnerships, pharmaceutical managers are better able to address a given
consumer need within the scope of the global brand. Further, they are better able to
navigate the complex and locally-driven processes that envelop drug development.
As discussed in earlier chapters, since it is the case that much of the innovation
within product development itself is centralized in pharmaceutical companies,
partnerships on the commercial side of the business are essential in order to effectively
bring a product to a specific market. The way in which local partnerships are used tends
to vary based on the country in which a product is being approved as well as the size of
the company itself. Distribution partnerships can be drawn upon if a given firm does not
have existing infrastructure in place in a particular location. In addition, local knowledge
can be critical to developing marketing strategies in a given region. As one interviewee
explained, while certain geographies are more physician-oriented because you need a
prescription for certain drugs (such as in the United States), places like India and China
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might need a different marketing strategy because pharmaceutical products are sold more
to affluent parts of society who pay for their own drugs, rather than to the masses.
Production and manufacturing partnerships exist because some countries require that a
drug be produced domestically if it is sold in that country. In addition, making products
locally has its strategic advantages, including avoidance of input tariffs and certain
regulations. One pharmaceutical manager pointed specifically to a technology transfer
product, whereby the technology a firm had developed in R&D was transferred to a
partner, and the partner would then make the product locally.
Respondents also explained that local partnering in the pharmaceutical sector
depends heavily on the size of the pharmaceutical company itself. According to
respondents, many mid-sized and small companies will often find a local partner to help
them with forward integration into a given market. This way, these smaller companies
can focus on what they are best at – R&D – while the partner can work on marketing and
selling the product in a region where they have core expertise. In contrast, managers
noted that larger pharmaceutical companies tended to have local teams wherever they
plan to distribute a product. Their sales force, with significant local knowledge and
infrastructure on the ground, could help them to tailor the product to the needs of that
market and culture without necessarily needing to rely heavily on local partnerships.
Finally, while most pharmaceutical managers noted the importance of
partnerships for commercialization, some also explained that partnerships could facilitate
a more efficient R&D process. In the development process, clinical trials can also be
undertaken in different parts of the world other than in the U.S. For example, one of my
respondents explained that when conducting trials for seasonal vaccines, the ability to
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operate in different geographies significantly accelerated the development timeline
because his firm was able to access infected patients throughout the year instead of only
in the winter months in the Northern hemisphere. As such, if a firm is able to conduct
clinical trials on a global basis, this can speed up the R&D process as a whole and create
a faster road to commercialization.
In the technology industry, my respondents explained that innovations are not
necessarily required to center on a company’s current scientific technology or formulas.
Rather, innovation in these companies could address any unmet need in the market.
However, the key to successful and efficient innovation in technology companies is
determining a needs gap in the precise market where one wants to serve an unmet need
and then aligning infrastructure and expertise to meet that need. Managers often bridge
the gap between consumer needs and company capabilities. A number of managers
described how they met directly with customers to determine what needs they hoped the
given product could fill for them. Managers then brought this information back to R&D
to determine to what extent the company had the capacity to address that specific need.
As my interviewees explained, local partners in the technology industry serve two
main roles in the innovation process of global companies. First, they might serve as
informants – to help a company better understand the market needs, opportunity, and
competition. Local partnerships can provide deep local knowledge to technology firms to
help create or alter technology to provide tailored and relevant solutions for customers.
Local partners can also serve as representatives for larger corporations. Local entities,
through their familiarity with the market, can help to obtain business for the larger
company and help to facilitate a relationship with the company and the end user.
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A number of my technology respondents pointed to the use of local partnerships
such as local sales teams or distributors, as a vehicle through which they could become
better informed about a given market and its potential opportunities. According my
participants, market knowledge should be based on a deep understanding of local needs,
which often vary dramatically by geography. Managers stated that some of the most
valuable input when creating products came from those partners closest to the customer.
Even managers with global sales teams advocated for the value of local partnerships. As
they explained, partners on the ground have familiarity with the region and can help map
the competitive landscape, impart insights on how to address a particular consumer base,
how to gain an advantage over competitors, and on the nuances of a particular region’s
cultures and values.
In addition, my interviewees pointed to the value of local partnerships in helping
those in the larger organization understand the markets and how to implement innovative
solutions. Local partners might even help to train and teach teams from the larger
organization who are working on the ground in a given location. Familiarity with local
regulatory protocol can also aid in making a service or product allowable in a given
location. In this way, local partners who can help multinationals navigate foreign
regulatory protocol were described as integral to a firm’s global success. Respondents
pointed to alliances with hospitals, academic sites, and research centers as well as
business alliances such as those with local resellers and manufacturers as critical sources
of information for innovating effectively. Further, before bringing a product to market in
a specific region, a number of managers suggested identifying and collaborating with key
influencers in a given market. These opinion leaders are those who would adopt a firm’s

	
  

71	
  

product first and would later serve as an example for the rest of the field. As such, their
opinions would be key when building a product. In sum, my interviewees felt strongly
that local partners could provide market intelligence, knowledge, and scaling ability.
Beyond the role of informant, local partners in the technology space were also
described as serving a representative role during the sales process. As my interviewees
explained, in markets with a different language or with different cultural norms than the
home market of a company, global firms will tend to foster relationships with local
companies to act as representatives in the region and to help opportunities emerge and
progress there. Further, global businesses tend to depend heavily on the efficacy of
partnerships because regional sellers have relationships with the end users that, in turn,
bring sales for the larger company. Local partnerships can also provide technical support
in a given region for local customers. According to technology managers, partners on the
ground can prove useful in certain markets if they have an existing established brand and
local connections. The larger multinational company might provide capital, expertise, and
products and the partner would stamp the products with their brand so customers would
feel comfortable purchasing them.

Partnerships: Intellectual Property Risks
Respondents in both the technology and pharmaceutical spaces advocated for the
importance of local partnerships in the efficiency and efficacy of innovation strategies.
However, the creation of local partnerships does not come without risks that have the
potential to seriously impact a firm’s profits and market share. For both technology and
pharmaceutical firms, the most important asset that they lay claim to is their intellectual
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property. Thus, when working with local partners and sharing information, ideas, and
market insights, my interviewees conveyed that great caution must be taken to protect
proprietary information.
According to technology respondents, when working with staff and regional
partners, one must be incredibly careful about the information that is shared regarding
new products. This is particularly important in the early stages of the innovation cycle.
During these stages, information-sharing should be primarily one-sided; that is, firms
should collect information from their partners, but remain vigilant and refrain from
exposing too much about the future. There is a delicate balance that leaders must manage
between maintaining partnerships and relationships, not over-sharing a firm’s ideas,
while still gaining information from partners to help the organization cultivate ideas for
new products. Because the protection of ideas is central to the survival of a technology
firm, some managers suggested centralizing R&D so as to better protect a firm’s
innovations. Some of my respondents stated that they chose not to create R&D centers in
certain parts of the world because they were concerned about idea appropriation. As one
interviewee explained, “we keep our research concentrated and closely-guarded because
if our technology is stolen, we will be out of business.”
In the pharmaceutical space, concerns about protecting the firm’s unique assets
were also related to how they engaged with partners. As these interviewees explained,
one of the biggest challenges for the industry relates to intellectual property protection.
The very first step to innovation in pharmaceutical companies, which illustrates the
importance of intellectual property in this industry, is a Freedom to Operate Assessment.
This assessment determines whether an idea like the one a firm is proposing has already

	
  

73	
  

been patented, how close this firm’s molecule is to another patented molecule, and how
well this product could theoretically be protected around the world. In relation to
partnerships, controlling intellectual property involves tightly regulating who has the
formula to make a specific product and the mechanisms to make it. As one respondent
noted, “while the discovery of the product is in the patent, the full recipe is not;” often,
important know-how required for the production of a drug is not fully available to anyone
other than the patent-holding company. Intellectual property can be protected through the
use of reputable partners, which can be discovered through a thorough investigation and
due diligence process or can be developed over time through long-term relationships.
One pharmaceutical manager pointed to a general need to increase global
awareness and appreciation for innovation and intellectual property rights in the industry.
As this interviewee explained, innovation can and should occur in any country, but it is
focused in places such as the U.S. and Western Europe because policies elsewhere need
to be altered. In many places around the world, intellectual property is seen as an asset
that can be traded in negotiations. It is in the best interest of all countries to protect one
others’ intellectual property because this, in turn, will result in a reciprocated protection
of the hard work and research of domestic innovators when they bring their ideas abroad.
My interviewees also expressed that illegal copying of drugs is a major issue in
the pharmaceutical space. As these respondents described, many companies, centered in
locations such as China and India, make generic versions of drugs that are of high quality
and are sold to the broader population for a lower price by these companies. If a country
only receives expensive drugs in return for protecting intellectual property, this is
unlikely to lead to stronger intellectual property regulation. Rather, as my interviewees
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advocated, to incentivize a bolstering of intellectual property regulation, firms and
policy-makers alike should disseminate the idea of reciprocal protection; if a country
bolsters its regulations at home, countries abroad will also strengthen their regulations,
creating a better global environment for innovation as a whole.
My pharmaceutical interviewees also explained that when working with local
partners, outsourcing production and selling pharmaceutical products in a particular
country largely depends on the strength of the intellectual property system in a given
geographic region. Additionally, the strength of the judicial system comes into play when
determining where to outsource and sell. If an intellectual property contract is put in
place but the judicial system is weak, it is unlikely that there will be strong repercussions
for a violation of that contract. As a result, companies are deterred from producing and
doing business in that given country or geographic region. Further, if a patent is not
enforceable in a particular geographic region due to a weak intellectual property or
judicial system, companies may be reluctant to sell in that country anyway because
product replication is a likely outcome. In this way, weak intellectual property systems
are actually a detriment to innovation. If a firm cannot be sure that it will be able to sell
its own innovation without someone else replicating the product, this in turn reduces
incentives to innovate for that particular market.
The issue of selling in geographies that protect property rights versus providing
medicines at affordable prices to consumers is a difficult dilemma, one that a number of
my respondents reported struggling with on a regular basis. Some respondents were
pessimistic about the outlook of intellectual property rights protection in some areas of
the world. They argued that in certain countries, the reality is that intellectual property
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cannot be protected. Thus, the cost of doing business in that area is recognizing that your
intellectual property will be vulnerable to copying or to government authorization of a
generic because the pricing policy does not favor domestic consumers. If a company
decided not to do business in a country because of a weak intellectual property regime, it
is likely that another firm would come in and corner that market for a particular need.
Others argued that intellectual property was also a moral issue in the pharmaceutical
industry; the provision of certain medicines should be a basic human right, according to
these respondents. In this way, protecting intellectual property to promote innovation can
also be seen as restricting access to certain medicines for certain populations. While there
was no consensus on how to actually manage this dilemma, it seemed that managers dealt
with the issue on a case-by-case basis, depending on the company, the region, and the
medicine being sold.
Brazil is one example my respondents shared of a geographic region that could
benefit highly from a strengthening of its intellectual property regulation. While Brazil
has made significant strides in innovation, Brazilians, my interviewee explained, tend to
do research for the sake of publishing. While publishing is a viable reason to undertake
research, Brazilians could also benefit from commercializing their research. Thus, if
Brazil was able to bolster its intellectual property regulations, not only would it likely
incentivize an increase in investment and foreign business within its borders, but it could
also profit further from its own unique innovations.
In sum, both the technology and pharmaceutical interviewees stressed the
importance of vigilant protection of intellectual property rights when operating on a
global scale. While technology respondents seemed to focus on intellectual property as it
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related to their local partnerships, pharmaceutical managers focused primarily on the
regulation of intellectual property itself. While intellectual property risks may be inherent
in the innovation process in both industries, it seems that a bolstering of regulation could
help to incentivize innovation and could lead to a wider dispersion of new ideas and
products across the globe.

Table 5: Managing Local Partnerships
Research Question 3:
To what extent do managers use local partners to implement their global innovation
strategies? Are there tensions associated with doing so? In particular, how does the firm
protect intellectual property when engaging with local partners?
Pharmaceuticals

Technology

• Help to better understand a
given market, local needs,
competition, drug approval
processes, reimbursement
schemes, regulatory path,
commercialization methods

• Provide deep local
knowledge for product
adaptation; help to
better understand
market needs,
opportunity,
competition

• Commercialization
partnerships – production,
manufacturing, marketing,
distribution, R&D
efficiency
• Dependent on company size

• Help obtain business for
larger organization,
facilitate relationships
between company and
end users
• Partnerships with local
sales teams, distributors

• Need to tightly regulate
who has specific know-how
required to produce drug in
certain geographies

• Balance between
maintaining local
partnerships and
gaining information
from partners without
over-sharing

Major Themes
Partners as Informants

Partners as Representatives

Intellectual Property Risks
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Chapter 8: Discussion
This thesis focused on understanding how to manage innovation globally and sought
to uncover the kinds of tensions and challenges managers face when leading across
markets globally. To do so, I engaged in a process of exploration through in-depth
interviews with top level leaders in two sectors – pharmaceuticals and technology. Using
a comparative lens, I sought to uncover key themes that were similar across respondents
from both of these sectors as well as differences. As innovation is central to my work, I
begin with a discussion of how my respondents defined innovation across the two sectors.
Following, I discuss the main themes that addressed the core research questions that were
central to my work. My first question examines the tension between innovating to meet
the needs of lower income consumers versus maintaining brand reputation worldwide.
Second, I analyzed the kinds of tensions managers involved in global innovation
strategies face in terms of adapting their own personal leadership style as they cross
market cultures. Finally, I asked respondents about their use (or lack thereof) of local
partnerships and of the management and mitigation of intellectual property risks
associated with partnering locally. After highlighting the key themes for each research
question, I discuss how these themes that emerged from my results reflect and/or extend
prior literature that relates to my key findings.
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Conceptualizations of Innovation
To begin, I focus on the results of my research with respect to core definitions of
innovation and I follow with how my findings relate to prior literature. Many of my
respondents emphasized that innovation requires delivering new value to the market. This
emerged as a key theme in both sectors that I studied when respondents discussed their
definitions of innovation. In the case of technology, respondents focused on the delivery
of new value by finding the intersection between what was technically possible for a
company and what the consumer valued most. Respondents also spoke to a less dramatic
form of innovation that involved adapting and improving upon current successful
technologies to address new problems. Pharmaceutical respondents similarly discussed
altering successful products to address new markets but also discussed creating new
pathways to address problems that existed already in the market. In both cases, my results
suggest that there is a keen focus on innovating in ways that ensure that the companies
attend to what consumers value most.
In some respects, these conceptualizations of innovation mirror prior research and
in other respects, they do not. Respondents in my sample characterized innovation with
definitions that reflected a combination of efficient innovation, which is somewhat
reflective of frugal innovation (Radjou & Prabhu, 2013) – where the focus is on
efficiently engaging in new ideas – and also the underpinnings of reverse innovation
(Govindarajan and Trimble, 2012), where an idea is taken from one market segment, be it
a technology or an idea, to serve consumers in another market. In the former case,
respondents seemed focused on cost-effective innovation, which is reflective of concepts
central to frugal innovation. In the latter case, respondents also discussed the idea of
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spreading their good ideas to new markets, mirroring the foundations of reverse
innovation. I note that in my interviews my respondents did not emphasize in particular
innovation that stemmed from emerging markets and then moved to developed country
markets.
Across both sectors, a number of respondents advocated for a conservative
approach to innovation that could be termed “incremental innovation” (OECD, 2002).
Respondents stressed the importance of taking risks while remaining ‘safe’ - that is,
innovating without undermining their successful reputation or alienating core consumers.
Thus, my results suggest that leaders face very real tensions associated with innovating
for new markets and so, in some respects, they were eager to follow an approach that was
both efficient and effective. I will return to this notion of risk-taking as a central theme
throughout my discussion, when I address the organizational structures respondents have
employed to carefully manage innovation.
For a majority of my respondents, the importance of creating an organizational
culture of innovation across their global companies was mentioned without my
prompting. Although my focus was largely on the structures that support innovation, as I
will describe next, my participants also emphasized the significance of having core
values and beliefs that were reflective of the larger organization’s culture even when
operating in multiple geographies. Prior research on culture suggests that culture can be
thought of as the informal structure of a firm or the norms and beliefs that govern the
ways in which individuals behave (Schein, 2010). Research on innovation suggests that
culture is critical to enabling a company of any size, industry, or geography to succeed
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and, if correctly and thoroughly instilled across the organization, can provide a firm with
a significant competitive advantage over the opposition (Tushman and O’Reilly, 2002).
In my sample, I found that there were some differences in how my respondents
talked about the importance of culture and there were some similarities as well. In terms
of similarities, both sets of respondents talked about the importance of appreciating
different backgrounds, viewpoints, and ways of thinking, and they discussed the value of
having people from different backgrounds and country contexts in order to do so. Prior
research has found that diversity is related to innovation. For example, work by Ayres
and Nalebuff (2003) has shown that teams that are composed of people from different
backgrounds do tend to come up with more innovative solutions to complex problems;
groups made up of individuals with varying perspectives will generally outperform those
more innately talented . Similarly, a number of my respondents explained that they tend
to hire diverse teams of individuals when establishing teams so as to generate a wider
range of potential ideas for product development.
While technology managers suggested that their firm was either risk-prone or
risk-averse in relation to the ways in which they innovated, pharmaceutical managers
spoke to a shifting risk profile. In technology firms, results from my interviews suggest
that it is the executives who determine the risk profile of a given firm. In contrast, in
pharmaceuticals, the stage in the firm’s cycle of innovation or product life cycle governs
how resistant or prone a firm might be to developing radical innovations. These
differences suggest that there may be ways in which the organization’s culture can shift
with time, depending upon the development stage of an innovation. These results extend
prior work and suggest new opportunities for research as well. Although many scholars
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seem to discuss organizational culture as an innate aspect of the work environment
(Schein, 2010), it seems that future research could examine in greater depth how that
organizational culture naturally evolves and is dynamic, depending upon the stage of a
company’s innovation efforts.
As expected, respondents did have a lot to say about how the structure of their
firms had encouraged or might encourage innovation. A central theme here was that
global managers felt the need to determine how to enable creativity to flourish in their
firms. There were some differences in how this played out across the two sectors. In
particular, a number of technology managers pointed to the creation of innovation
subunits whose role would entail connecting to customers while also mitigating risk for
the larger organization. In essence, these subunits could be seen as safe spaces for
innovating and testing concepts. Some technology interviewees, similar to most of my
pharmaceutical company interviewees, advocated for a centralization of R&D centers to
allow streamlined and efficient collaboration for idea generation. Further, a number of
pharmaceutical respondents attributed the size of a company to largely affecting its
innovative capabilities; smaller companies were viewed as engines for innovation while
larger, later-stage companies were more focused toward the purchase and
commercialization of innovations.
My findings echo the research on innovation and MNCs, which has emphasized
the tensions that managers face in creating structures that enable them to garner new
ideas from the field while also maintaining mechanisms that allow for efficiency and
consistency across markets and product lines. For example, prior research by Kotter
(2014) suggests that large companies do have difficulty encouraging innovation and so,
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should find ways to structurally enable creative ideas to get to senior management. In his
work on “acceleration,” Kotter discusses the idea of creating separate filtering units that
would encourage and then sift through new ideas before they came to management for
consideration (Kotter, 2014). This work is a new approach to encouraging innovation and
could be applied to strands of what I heard from my participants. That is, in technology,
there was an emphasis on ensuring that subunit structures were in place that were closest
to the customer and then allow for ideas to filter up. However, these respondents were
less specific about how, exactly, that filtering would occur.
On the other hand, in the global pharmaceuticals companies, there was a greater
emphasis on centralization to ensure that efficiencies would be managed appropriately.
These findings reflect some of the research by Grossman and Rangan (2001) who argue
that multinational firms need to ensure that ideas developed by separate units or functions
are “integrated” into the larger corporate structure. It seems that for pharmaceutical
companies, at least in my sample, integration was a key concern that could be addressed,
at least in part, by centralizing R&D. Some of my findings and the tensions that managers
seemed to be facing in developing these kinds of “ambidextrous” structures (Tushman
and O’Reilly, 2004) reflect early research on large corporations that emphasized the need
for both “integration” and “differentiation” (Lawrence and Lorsch, 1986). While
differentiation within the organization would allow for autonomous business units to
attend to various market segments, they needed to be sufficiently integrated into the
larger corporation for the business model to be successfully implemented.
These findings suggest opportunities for future work. Future research might
explore if and how global managers strive for integration and differentiation using
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different structures that both promote innovation and also allow for efficiencies and
coordination of operations. Given the differences that I found across sectors, additional
research might explore if and how structures might need to change with the kinds of
products offered or with the stages of an innovation’s life cycle.

Serving Multiple Customer Needs
My second set of research findings revolved around the question of how to
effectively innovate to meet the needs of multiple consumer bases. One of the core
findings was the tension that global managers faced regarding the desire to help their
firms serve multiple customer needs without undermining the global company’s brand
and reputation. For example, in the technology space, respondents spoke to creating
similar products with numerous variations of features and pricing to address varying
levels of affordability. Others believed that creating products that could span multiple
geographies would allow for companies to address multiple needs without diluting the
larger organizational brand.
According to my respondents in pharmaceuticals, brands of each individual
product are not necessarily linked to the brand of the larger organization. Thus, marketing
and messaging tends to revolve around bolstering the brand of a specific product rather
than that of the larger firm itself. However, some participants believed that the brand of
an organization could be positively or negatively affected depending on the ways in
which the firm chose to operate. For example, respondents pointed to corporate social
responsibility (CSR) programs and pricing policies that were favorable to lower-income
consumers as ways to improve brand reputation for the larger organization.
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My findings align well with prior research on innovation that has examined
similar tensions regarding how global companies can attend to varying needs in different
geographies. For example, the research on glocalization suggests that innovations
originating in established markets can be transferred to the developing world and enable
firms to address needs in both developed and emerging markets (Robertson, 1995).
Similarly, the work on reverse innovation speaks specifically to the idea that innovation
created originally for emerging markets can ultimately be scaled and appropriated by the
developed world (Govindarajan and Trimble, 2012).
Further, some of my findings reflect the research stream on Corporate Social
Responsibility (CSR). For example, results from my interviews with pharmaceutical
senior managers suggest that they were interested in the CSR of their firms, as they
considered ways in which their products might need to be modified depending on local
markets given the price point of the products being offered and the demographics of
markets. Their comments reflect some of the tensions discussed in the literature on CSR,
which has shown that those companies that engage in CSR initiatives may reap positive
benefits for the company’s reputation. However, there are limits to the effectiveness of
this kind of activity if it is not carefully managed (Bhattacharya and Sen, 2001). Clearly,
serving multiple markets at once, which is often the case in global companies, presents
challenges for global managers that are much more complicated than simply bifurcating
or segmenting the market and running operations in separate business units; the
integration of these strategies and operations are important to consider as well.
My findings also suggest that serving multiple customers entails some tensions
that are unique to multinational companies - specifically, the tensions associated with

	
  

86	
  

globalization versus localization – which parallel some of the research on MNCs. As my
respondents told me, there are significant incentives associated with customizing
products for local needs in different country contexts. At the same time, since MNCs
possess a global brand and global operations, thoughtful consideration must be paid to
how brand and operations are managed on a global and local scale.
In my technology interviews, a spectrum of views surfaced on this topic. While
some respondents placed a high value on tailoring products specifically for a given
market, others were more focused on creating the most efficient or cost-effective strategy
for a firm’s operations. In the case of pharmaceutical companies, because the formula
behind the medicine itself did not tend to shift depending on the geography in which it
was being sold, adaptations occurred on the commercial side of the business. A majority
of my participants pointed to the importance of altering marketing, sales force,
administration, and pricing strategies based on the needs in a certain geography, in order
to capture the largest market share possible in a given part of the world.
These findings seem to echo the international research conducted by Garvin and
Levesque (2008) focusing on global - local tensions within MNCs. Their findings reflect
responses from my pharmaceutical managers who believed that tailoring the commercial
aspects of innovation was essential for success in different geographies because varying
demographics affect values and needs. Research findings by academics such as
Govindarajan and Trimble (2012) tend to fall on the local customization end of the global
versus local trade-off spectrum. Their work points to five needs gaps that create
opportunities for customization and should encourage firms to create innovations that are
adapted for local needs (Govindarajan and Trimble, 2012). Further, Allen (2012)

	
  

87	
  

advocates for localization as well, suggesting that “differentiation is found in what you do
for your customers each day” (Allen, 2012; p. 1). Thus, scholars who focus on MNCs
have recognized trade-offs associated with operating on a global scale for some time. My
results also suggest that perhaps how organizations decide to address these needs gaps
may actually stem from the prior organizational experiences of the global managers
themselves.
Another key issue that has surfaced in scholarly literature is the extent to which
the management in large companies can become cognitively entrenched in a conservative
mindset and have difficulty changing or moving in innovative directions (Tushman and
O’Reilly, 2002). Govindarajan and Trimble (2012) suggest that one of the critical
concerns for any company trying to innovate is the extent to which the organization can
actually change its “dominant logic” of operating, based on previous successes and
antiquated beliefs. Dominant logic can serve as a self-imposed constraint in the pursuit of
novel innovation (Govindarajan and Trimble, 2012).
In my interviews, however, only the technology managers made any mention of
entrenched mindsets in response to my questions. For example, the technology leaders
discussed how a desire to protect the status quo and prior successes of a firm by
executives within the organization could stifle the innovation process, particularly within
larger technology organizations. In contrast, for my pharmaceutical interviewees, rather
than pointing to an entrenched mindset as a tension inherent in innovating, they stated
that a desire to protect the status quo might come at a certain juncture in the company's
lifecycle after the firm has produced and commercialized a successful medicine. This
difference in perspective was surprising and may call for further research to better
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understand why and how such resistance to change may be more or less prevalent in
different industries.
A final key finding regarding my question about serving multiple customer needs
revolved around themes associated with how companies innovated for a specific
consumer base. This is similar to the prior theme regarding global-local market tensions
but here, the emphasis is on how companies actually did that work. In both instances,
global managers repeatedly mentioned the significance of communication to ensure that
they were indeed serving the needs of particular consumers. Interestingly, in the case of
the technology firms, respondents emphasized internal communication, whereas in the
case of the pharmaceutical firms, respondents mentioned external communication more
often as a necessity for remaining at the forefront of the industry in terms of coming up
with innovative and exciting ideas that could serve global markets.
Prior research on communication within multinational companies has shown that
effective internal and external communication are critical to innovative performance in
organizations (Kivimaki et al., 2000). Other research on teams working in uncertain
contexts, such as healthcare, has shown that finding ways to increase the flow of
information and ideas within teams and business units is critical to organizational
learning and to solving complex problems (Garvin, Edmondson, Gino, 2008). While
difficult, my respondents felt this knowledge transfer was key to the success of their
innovation.
In the case of the pharmaceutical companies, the emphasis on external
communication with academics reflects the need to learn from outsiders whose work
delves into information regarding various scientific areas. Berchicci (2013) claims that it
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is critical for organizations to have information that comes from beyond the boundaries
of the firm itself in order to solve complicated problems. His work demonstrates that a
reliance on external R&D (to a point) improves the innovative performance of a firm
(Berchicci, 2013). Thus, my findings do echo prior research on the need for informationsharing both within and beyond the organization. However, the differences across the
sectors in terms of the emphasis that respondents placed on internal versus external
communication was unexpected and may warrant further research.

Leading Across Cultures
One of the core questions I had in this research was the how managers actually
lead in a global environment. Across my interviews, I heard how critical it was to become
effective at adapting one’s leadership style to suit local customs and cultures and,
additionally, how this took time, patience and active listening to learn how to do. In both
sectors, respondents shared stories with me about how they learned the local culture,
sometimes through experiences such as sharing a meal with local customers, partners, or
clients, and sometimes through hearing others’ experiences.
These stories and reflections are consistent with scholarship on leadership that has
stressed the importance of learning about other cultures and demonstrating empathy in
one’s work. The skills needed to manage globally are discussed as “managing crossculturally.” Scholars have found that the need for “culturally adept” employees is on the
rise and that cultural intelligence is malleable and can be learned (Ramsey & Lorenz,
2016). Prior research suggests that, similar to the stories that I heard in which people
learned to modify their leadership behavior, people who have high Cultural Intelligence
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(CQ) – an ability to operate in multi-cultural environments and groups and to interact
cross-culturally – are able to adjust “in the moment” and so, adapt effectively (Ramsey &
Lorenz, 2016).
From a business and organization-level perspective, respondents discussed the
need to understand local customs and adapt, all the while maintaining a common
corporate culture across international boundaries. The need to maintain this balance
reflects research by Grossman and Rangan (2001) that demonstrates that while
customizing leadership depending on geography is important, maintaining consistent
standards and values across an organization can help unify and strengthen the firm as a
whole. Additionally, Kanter’s research (2010) suggests that it is critical for leaders to
invest time with employees in the locations in which the firm does business. Face-to-face
interactions will facilitate an environment of trust within the organization and allow
managers to engage in “identity work” whereby leaders will come to better understand
the linguistic and social differences of employees that exist across borders. Leaders who
acknowledge, understand, and adapt to these differences, according to Kanter, may in fact
enable and encourage individuals to express their ideas and innovate (Kanter, 2010).
The challenge of managing across cultures reflects a prior tension discussed,
which was the theme of serving multiple customers both globally and locally. The tension
that firms face when creating products with a global brand that are also tailored to fit
specific markets parallels the duality that leaders must manage when leading across
borders; managers must maintain a certain equilibrium between the global corporate
culture while adapting management to fit needs within different cultural environments. In
these ways, my findings reflect previous scholarship and suggest that, with future
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research, there may be some additional insights that could be gleaned as to how these
kinds of culture-crossing activities that global managers must engage in constantly
impacts their own leadership style over time and perhaps even their own identities.

Managing Local Partnerships
The results from my research also revolved around the core question of, to what
extent do managers use local partnerships to implement their global innovation strategies.
Here, I found that my interviewees were very interested in discussing the benefits and
roles of having partners when managing across geographic regions and across cultures.
One key role emphasized in both sectors was the function of partners as informants who
could help a company better understand a particular market, its needs, opportunities, and
competition. Additionally, managers in both sectors suggested that local partners could
also serve as representatives on the commercial side of the innovation process. In this
way, local partners could help the organization obtain business by facilitating
relationships with the end-users, and could also help with the implementation of relevant
distribution mechanisms and marketing strategies.
My findings are reflective of some of the prior research on partnerships or
strategic alliances. For example, prior research has demonstrated that firms enter into
alliances or partnerships in order to gain access to new information and resources, and
that these alliances are particularly critical in highly uncertain environments (Gulati,
2007), which one could argue is the case when a company is trying to innovate. In this
case, the partnerships that my respondents discussed were deemed important in this
context of innovation to reduce uncertainties associated with new markets and to gain
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knowledge necessary for the business (Mowrey, Oxley, and Silverman, 1996). In
addition, my findings echo prior research by Morten and Birkinshaw (2007) who show
that companies can capitalize on partnerships with external entities such as universities,
government labs, entrepreneurs, and even customers themselves to learn about emerging
ideas and generate unique concepts and products. This sort of knowledge exchange and
collaboration can allow a firm to tap into sources of knowledge that will keep its
innovations relevant and the organization as a whole at the forefront of the industry
(Morten and Birkinshaw, 2007), which is similar to what I heard from my respondents in
both sectors.
Finally, my respondents noted that while partnerships are essential for success in
a global market, there are significant risks associated with entering into them. One of the
most significant risks associated with partnerships relates to intellectual property, in both
the technology and pharmaceutical industries. This is largely because the most important
asset that firms in these global and uncertain contexts own is their intellectual property.
Findings from my interviews align well with prior research that has examined the
benefits and costs of alliances. For example, research on alliances has shown that there is
oftentimes a tension between cooperation and competition that must be managed and
taken into consideration when entering into partnerships (Khanna, Gulati, Nohria, 1998).
In my sample, there was evidence of these kinds of concerns as some technology
respondents talked about the ways in which they maintained primarily one-sided
information-sharing with partners in the early stages of a product’s development so as to
protect over-exposure of the firm’s innovation. In future research, it could be helpful to
delve more deeply into if and how certain kinds of partnerships presented opportunities
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for collaboration as opposed to competition and how global managers deal with this
delicate balance as it relates to expectations and norms in certain country contexts. It
could be that in some countries, collaboration is more generally expected and in others,
competition is more often the norm among partners. The potential for country-level
differences in the use of partnerships might be useful to explore in future research and
could be helpful to leaders who must navigate partnerships in multiple country contexts
on a daily basis.

Limitations and Suggestions for Future Research
Although my research design had several strengths, including the breadth of the
organizations from which I was able to garner interviews and the senior level of the
interviewees, who were difficult to reach and find time in their busy schedules, there
were several limitations to this research as well. First, the examination of my research
questions was limited due to a small sample of twenty respondents. Although these were
in-depth interviews that lasted approximately 45 minutes in length, this research would
have been richer had there been more interviewees in total.
Therefore, future research into these areas of inquiry could benefit from a larger
sample size and respondents stemming from other industries. This larger and more
diversified sample size could provide a better understanding of the generalizability of
some of my findings. Alternatively, future research could engage in additional interviews
in these same sectors but with more leaders at different levels of similar organizations to
understand if and how the tensions uncovered here might play out differently at different
levels of an organization. It is likely that the tensions that presented themselves in my
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findings are more pronounced at the senior management level rather than at the local
level of management because of the nature of these tensions. The challenges that arose in
my study were those associated with managing on a global scale within a multinational
firm. I would hypothesize that an array of other challenges might present themselves for
leaders at the local level as they work to manage their individual groups. At the same
time and despite the small sample size of my study, this study was an effort to explore
rather than definitively test hypotheses, and so, I am hopeful that my findings are able to
provide insight into some of the tensions that leaders of multinational firms face and to
generate future research interest.
I was also limited by the nature of the data. I was fortunate to be able to gain
access to very senior level executives in both the technology and pharmaceutical spaces.
However, because the data were purely qualitative, and therefore did not contain
quantitative aspects, it is difficult to discern the impact or benefit of the various ideas
suggested in my interviews. Future research could use a mixed method approach to my
areas of inquiry; this would require determining quantitative measures of, for example,
the different markets served. Creating a quantitative study to further this research could
include surveys that would ask respondents to report on similar scales the extent to which
they experienced certain tensions uncovered in this research. Moreover, gathering data
from both the upper and lower levels of management could help to better understand
whether these challenges are typically widespread across management within an
organization or more pronounced at certain levels. Further, with quantitative data
collected over time on certain kinds of market expansions and their impact, we might
learn more about how innovations are introduced and managed differently over time.
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More generally, a mixed methods approach might help us uncover additional tensions
associated with innovating on a global scale in multinational corporations.
Finally, my sample was built from a snowball sampling technique, whereby my
network of contacts was built out as I spoke to more interviewees. While this sampling
technique provided breadth and depth to explore my areas of inquiry, conversations were
more opportunistic than originally anticipated. Thus, as previously discussed, not all of
my interviewees were necessarily in the process of serving underserved markets. Still,
many of the lessons from my interviews seem plausibly generalizable to the broader field
of innovation management within multinational corporations. Future research that is able
to more narrowly select leaders who were all operating in similar geographic regions
could build upon this research to examine if there are separate and useful lessons to be
learned about transferring or creating innovations in underserved markets for developed
markets, or the reverse.
Conclusion
The findings from this study provide evidence that research into the management
of innovation in multinational corporations, such as the study of organizational structures
to promote idea generation, can help us to begin to understand how to best address the
complex and diverse needs that exist in our increasingly globalized world. Whether or not
an organization is risk-prone, risk-averse, or somewhere in the middle, it is evident that
the future of innovation and product development will include unraveling the intricacies
of successfully leading transnational innovation strategies.
One of the core overarching themes that this research uncovered is the idea that
paradoxes or tensions are ever-present for leaders of global organizations today. I began
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this research with the sense that there may be tensions in adapting to local needs in
product development while maintaining a global brand and global operations. However,
what I found in my work is that this notion of tensions extended far beyond what I
originally anticipated. For example, in terms of creating a corporate culture of innovation,
leaders talked about maintaining a global organizational culture while recognizing and
empathizing with local cultures of individuals within the firm. In terms of leading for
global innovation, they talked about retaining their dominant and unique leadership style,
while also being adept at tailoring their style to suit different country contexts. Even in
discussions of the content of the innovation itself, leaders explained how products often
needed to span geographies but at the same time address the needs of specific geographic
markets, with their unique values and needs. And, in terms of partnerships, my findings
uncovered a core tension around fostering collaboration when there was the possibility of
competition.
After further examination of my findings, it seems that these tensions or
paradoxes are actually made up of interdependent elements. For leaders I spoke with,
these elements, some complementary and others contradictory, did not require choosing
one or the other, but rather, maintaining a sort of equilibrium between different elements
that made up these tensions. For example, global leaders expressed the need to maintain a
global corporate culture and also be able to encourage local subcultures to emerge in
certain country contexts or in smaller business units. In this way, these organizational
tensions could instead be viewed as dualities rather than paradoxes that need to be
resolved – dualities that coexist in the operations of multinational corporations and are
interconnected in nature.
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The organizational dualities that have been unveiled in this study, particularly in
relation to innovation, are representative of the challenges and opportunities that present
themselves when operating on a global scale. Future research that examines the topic of
paradoxes as dualities in the context of global management might further my research.
Just as there has been a rise in training leaders to develop a Cultural Intelligence (CQ)
(Ramsey & Lorenz, 2016), there could be implications for how leaders are developed
such that they become adept at finding ways to coordinate or integrate different
structures, cultures, and leadership styles as they manage global firms. And, in the case of
managing for innovation, my expectation is that these kinds of dualities will only be that
much more challenging as managers face the duality of leading for “new” ideas while
preserving their core mission and previous successes.
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Appendix A: Thesis Overview Shared with Interviewees
For my honors thesis, I am studying how managers and leaders of global firms manage
innovation in multiple markets, especially in both developed and emerging markets. I am
particularly interested in the kinds of tensions that managers of innovation strategies face
as they try to implement innovation strategies worldwide within their firms.
Current research on multinational corporations (MNCs) provides an understanding of
different kinds of innovation and the ways to attend to multiple markets. However, there
is less documentation of how these innovation strategies are actually implemented on the
ground and the tensions that these efforts might produce. For example, substantial
research on innovation by Vijay Govindarajan and Chris Trimble has examined the
theory of “reverse innovation,” where firms focus on local customization and innovate
specifically for the needs of emerging market consumers. Others, including Michael
Tushman and Charles O'Reilly, have also looked at global firms’ “ambidexterity” in
attending to multiple market needs at once. Scholars such as Garvin and Haas
demonstrate the difficulties that managers face in coordinating communication and
information flows across international borders and cultures. However, there is little
research that pulls these streams of work together or that looks at how coordination and
communication issues that condition a firm’s implementation of a global innovation
strategy.
For my work, I am interested in three kinds of tensions that I believe that managers of
global companies may face when implementing a global innovation strategy. These could
be stated as “hypotheses,” although they are likely more similar to areas of inquiry. I
have outlined these three areas below. On the next page, I have included specific
questions for your consideration that I plan to use in my interview process.
1. Is there tension between innovating to meet the needs of lower income consumers
versus maintaining brand reputation worldwide; if so, how would these be
described?
2. What kinds of tensions do managers involved in global innovation strategies face
in terms of adapting their own personal leadership style as they cross market
cultures?
3. To what extent do managers use local partners to implement their global
innovation strategies? Are there tensions associated with doing so? In particular,
how does the firm protect intellectual property when engaging with local
partners?
Through this research, I hope to contribute to a better understanding of how companies
can improve their ability to meet the needs of diverse consumers in both developed and
emerging markets. Further, I aim to contribute to the literature on the management of
innovation on a global scale. My focus is on the implementation of global innovation and
it is for this reason, given your role, that I believe speaking with you would be very
helpful.
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Overall, I expect the interview to last between 30 minutes and an hour in length and will
focus on the above-mentioned topics. A sample list of questions can be found on the
following page. Participant names will be kept anonymous unless the participant
indicates otherwise to the researcher. Thank you in advance for your consideration, and I
look forward to speaking with you.
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Appendix B: Interview Protocol and Sample Questions
Please describe your role in X company (current/past). In what ways were you involved
in global strategy work and, in particular, innovation that was going on at X company?
Can you describe the global innovation strategy you observed (or led) while you were at
X company? What were the priorities at the time and how did they shift while you were
there?
Can you describe a product or service that you would characterize as a strategic
innovation initiative – where a new product/service was developed and executed either in
the home market (e.g., United States) and then taken to another country or some other
strategy - when a product/service was developed separately for different markets?
Would you trace the evolution of this example/initiative in your company?
• Was it planned that this would be a global innovation initiative from the start or
did this just evolve that way over time?
• When was a team put together to work on this project?
• How did you select the team members?
• How did you divide up the work and why?
• How was this team managed? Led?
More generally, I am interested in the management of innovation at your company.
• How intentional has your company been in trying to innovate in different country
markets and why?
• Could you talk about the tensions that have arisen in your experience between
creating new innovations for underserved markets while also maintaining your
firm’s brand and reputation?
• More generally, how have you managed the tensions and risks that might be
associated with trying to meet local market needs while in a global company what has worked well/not so well, from our experience?
• What other tensions exist in this kind of global innovation work that we have not
discussed?
My work is also focused on examining the risks to a firm that may be associated with
partnering with local entities.
• In general, does your company work directly with local partners in a country they
might want to enter? Or, do they bring in people from corporate?
• What / who have been your most valuable partners on the ground?
• How / has your company coordinated information flows/transfer with these
partners? Are these kinds of partnerships managed differently and if so, how?
• What is critical to know about working with local partners when innovating or
implementing an innovation strategy in your field?
• Can you please walk me through the risks of working with different kinds of local
partnerships?
• Do you think your approach to serving different markets (other than the U.S.) is
unique to companies in your sector? Why/not?
	
  

101	
  

I am also interested in the leadership of global companies like X and the ways that people
might need to adapt their own styles or management when working across cultures
• In general, did you find that you had to adapt or alter your leadership style when
working in different cultures? If so, can you give an example of a time when you
did this? How did you go about altering your leadership style to conform to your
understanding of the cultural, political, social environment in a different country
context?
• What lessons do you take away from these kinds of experiences?
Did my questions miss any critical issues in managing innovation strategies globally?
Are there any other individuals that you think I could talk to about this topic?
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